

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07K 7/06, 7/08, 7/10 C07K 15/00, A61K 37/02, 39/00 G01N 33/68	A1	(11) International Publication Number: WO 93/11155 (43) International Publication Date: 10 June 1993 (10.06.93)
(21) International Application Number: PCT/GB92/02246 (22) International Filing Date: 3 December 1992 (03.12.92) (30) Priority data: 9125747.7 3 December 1991 (03.12.91) GB 9214663.8 10 July 1992 (10.07.92) GB (71) Applicant (for all designated States except US): PROTEUS MOLECULAR DESIGN LIMITED [GB/GB]; Proteus House, 48 Stockport Road, Marple, Cheshire SK6 6AB (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : FISHLEIGH, Robert, Vincent [GB/GB]; Bradley Smith Cottage, Gurnett, Macclesfield, Cheshire SK11 0HD (GB). ROBSON, Barry [GB/GB]; The Old Bakery, 22A Town Street, Marple Bridge, Cheshire SK6 5AA (GB). MEE, Roger, Paul [GB/GB]; 4 Park Gate Avenue, Withington, Manchester M20 9DZ (GB).		(74) Agent: FRANK B. DEHN & CO.; Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB). (81) Designated States: AU, BG, BR, CA, FI, HU, JP, MN, NO, NZ, RO, RU, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: FRAGMENTS OF PRION PROTEINS (57) Abstract Synthetic polypeptides having at least one antigenic site of a prion protein are disclosed together with methods for their use and manufacture and antibodies raised against such polypeptides. Diagnostic kits using the polypeptides and/or antibodies are also disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

- 1 -

FRAGMENTS OF PRION PROTEINS

5 The present invention relates to synthetic
polypeptides. In particular it relates to synthetic
polypeptides which emulate the three-dimensional
structures and/or electrostatic surfaces and/or other
physical, chemical and structural properties of specific
10 regions of proteins thought to be the involved in the
molecular pathology of spongiform encephalopathies. It
is of particular interest to the design of
immunodiagnostics, vaccines and other medical,
veterinary or scientific agents in relation to human,
15 bovine and ovine spongiform encephalopathies.

Spongiform encephalopathies are a group of
degenerative neurological diseases. Examples have been
found in a number of species including sheep (where it
is known as scrapie), cows (BSE) and humans
20 (Creutzfeldt-Jakob disease (CJD) and kuru) (Review
article, Taylor, D.M. Veterinary Record 125,413-415
(1989)). Similar conditions have also been found in the
wild mink population and in captive kudus (a kind of
antelope) and tigers. It has been variously reported
25 that BSE can be transmitted under laboratory conditions
to mice and pigs. This crossing of species barriers by
the infective agent has led to increased concern that
transfer to humans could occur.

These diseases are characterised by a slow
30 incubation time of four to five years after which the
clinical symptoms of progressive degeneration of mental
state, including aggressiveness and lack of
coordination, appear. Post mortems reveal a
characteristic pattern of vacuolation in brain tissue
35 due to the destruction of neural cells, and the
deposition of unusual protein fibres.

Although the form of the disease found in sheep

- 2 -

(scrapie) has been known for many years, spongiform encephalopathies have come to prominence within the last decade following the appearance of BSE in cattle farms. The incidence of BSE in the United Kingdom has increased
5 markedly during this period and public concern over the possible transmission of the disease to humans has led to a collapse in the beef market. Thus for both veterinary and economic reasons, there is an urgent need for diagnostic agents to detect infection and for
10 vaccines to prevent infection.

It is believed that the causative agent of scrapie and its counterparts in other animals is a so-called "prion", that is an infective particle comprising protein only and no nucleic acid, the presence of the
15 latter being required in the case of a conventional virus. In scrapie, one particular protein (termed prion protein, PrP^{Sc}) has been found to co-purify with infectivity and can produce a scrapie-like condition in brain cell cultures from other animals, such as
20 hamsters; under laboratory conditions. PrP^{Sc} is the only known component of the characteristic protein fibres deposited in the brain tissue of scrapie-infected sheep. The term "PrP^{Sc}" as used herein should be taken to refer not only to the specific Prion protein identified in
25 sheep but also to those homologous proteins found in many other species which appear to undergo a structural modification as described hereinafter. The term "PrP^C" shall be used in respect of the normal cellular counterpart to PrP^{Sc}.

30 The major problem in the search for a specific diagnostic agent or synthetic vaccine against the scrapie agent PrP^{Sc} is that it is almost identical to the natural form of the protein PrP^C. The natural function of this protein is not yet understood but the remarkably
35 strong conservation of primary structure between homologous proteins from different species suggests that it has an essential structural or functional role within

- 3 -

the organism.

In spite of the almost identical form of these prions to the natural proteins, we have deduced synthetic peptide structures comprising at least one antigenic property, such as an epitopic site and these synthetic peptides may be used to produce diagnostic agents and vaccines.

The responses of the B and T cells of the immune system are not specified by a global recognition of a whole protein but rather by recognition of a small region of the protein surface known as epitopic site. Such sites may be formed by a continuous section of peptide chain or may be discontinuous, where separated sections of peptide chain are brought together at the protein surface due to folding of the chain. One aim in producing a synthetic peptide vaccine is to mimic the structure of a particular epitope and thereby cause a primary immune response leading to the production of memory B cells which will secrete antibodies on subsequent exposure to the parent protein so producing a greatly enhanced response to secondary infection. A similar mechanism via priming of the cytotoxic T cells to respond more vigorously to a particular antigen will also occur.

However, problems exist with the application of traditional methods of vaccine production to this disease as it is believed that the molecular structure of the protein prion rather than nucleic acid sequence passes on infectivity in the prion. The usual method of viral vaccine production involves the inactivation of the virus in some way to destroy infectivity whilst preserving epitopic sites. Such techniques as heat treatment or serial passaging of the virus through a culture are used, but these approaches would not lead to a loss of infectivity of a prion unless conditions were such as to cause protein denaturation. If the conditions are severe enough to

- 4 -


inactivate the prion protein then denaturation of the protein occurs and any epitopic sites are lost. Thus there is a major problem in trying to obtain antigenic but non-infective prion proteins by conventional routes.

- 5 It is known, for example, that the scrapie agent in sheep is particularly resistant to chemical or physical inactivation (Hodgson, J. Bio/Technology 8 990 (1990)).

In one aspect our invention provides a synthetic polypeptide having at least one antigenic site of a
10 prion protein. Preferably the prion protein is of a form which only exists in nervous tissue of a mammal suffering from spongiform encephalopathy.

- We have found that prion proteins of the type mentioned above comprise six regions of interest,
15 labelled A to F, and two related frame shift peptide sequences, viz: 1) a repeating section in region E having undergone a nucleic acid coding sequence frame shift of +1 (FSa) and 2) the repeating section in region E having undergone a nucleic acid coding sequence frame shift
20 of -1 (FSb).

With regard to region A, our invention provides a synthetic peptide sequence according to general formula (I):



- 30 wherein R₁ is an amino acid residue selected from Met, Leu and Phe;

R₂ is either Met or Val;

R₃ is Ala or is absent;

- R₄ and R₅ are independently an amino acid residue
35 selected from Leu, Ile and Met; one or more residues within brackets maybe present or absent with the proviso that if they are present they are attached to the rest

- 5 -

of the peptide in sequence; and X and Y may each independently be absent or independently be one or more additional amino acid residues.

It will be apparent for example that the residues
 5 at the N-terminal of the sequence may be present as "R₂"-
 or "His-R₂-" or "Lys-His-R₂-" or "R₁-Lys-His-R₂-"
 Similarly, the preferable residues at the C-terminal may
 be present as "-Arg", or "-Arg-Pro", or "-Arg-Pro-R₄", or
 "-Arg-Pro-R₄-R₅."

10 Preferably, R₁, if present, is Met, R₃ is Ala and
 R₅, if present, is Ile. Also, if R₂ is Met then R₄, if
 present, is Ile. Below are preferred sequences (Seq.
 I.D. No: 1 and Seq. I.D. No: 2) of formula I relating to
 bovine and ovine and to human prion proteins
 15 respectively:

Seq. I.D. No: 1

X-(Met-Lys-His-Val)-Ala-Gly-Ala-Ala-Ala-Ala-Gly-Ala-
 Val-Val-Gly-Gly-Leu-Gly-Gly-Tyr-Met-Leu-Gly-Ser-Ala-
 20 Met-Ser-(Arg-Pro-Leu-Ile)-Y; and

Seq. I.D. No: 2

X-(Met-Lys-His-Met)-Ala-Gly-Ala-Ala-Ala-Ala-Gly-Ala-
 Val-Val-Gly-Gly-Leu-Gly-Gly-Tyr-Met-Leu-Gly-Ser-Ala-
 25 Met-Ser-(Arg-Pro-Ile-Ile)-Y.

A particularly preferred sequence according to
 formula I is Seq. I.D. No: 51

Lys-His-Met-Ala-Gly-Ala-Ala-Ala-Ala-ly-Ala-
 30 Val-Val-Gly-Gly-Leu-Gly-Gly-Tyr-Met-Leu-Gly-Ser-Ala-
 Met-Ser-Arg-Gly-Cys..

Naturally, our invention encompasses significant
 sub-fragments of the sequence according to formula I
 35 above and preferred sub-fragments are:

i) X-(His-R₂-Ala-Gly)-Ala-Ala-Ala-R₃-Gly-Ala-Val-

- 6 -

Val-(Gly-Gly-Leu-Gly)-Y and;

ii) X-(Gly-Gly-Leu-Gly)-Gly-Tyr-Met-Leu-Gly-Ser-
Ala-Met-Ser-(Arg-Pro-R₄-R₅)-Y

5

wherein R₂, R₃, R₄, R₅, X and Y are as defined for formula I and one or more residues in brackets may be absent or present as in formula I.

It will be clear from the foregoing that preferred
10 sub-fragments relating to both bovines and ovines are

Seq. I.D. No: 3

i) X-(His-Val-Ala-Gly)-Ala-Ala-Ala-Ala-Gly-Ala-
Val-Val-Gly-(Gly-Leu-Gly-Gly)-Y; and

15

Seq. I.D. No: 4

ii) (Gly-Gly-Leu-Gly)-Gly-Tyr-Met-Leu-Gly-Ser-
Ala-Met-Ser-(Arg-Pro-Leu-Ile)-Y.

20 Similarly, preferred sub-fragments for humans are:

Seq. I.D. No: 5

i) X-(His-Met-Ala-Gly)-Ala-Ala-Ala-Ala-Gly-Ala-
Val-Val-Gly-(Gly-Leu-Gly-Gly)-Y; and

25

Seq. I.D. No: 6

ii) X-(Gly-Gly-Leu-Gly)-Gly-Tyr-Met-Leu-Gly-Ser-
Ala-Met-Ser-(Arg-Pro-Ile-Ile)-Y.

30 With regard to region B, our invention provides a
synthetic peptide sequence according to general formula
II:

X-(Ser-Ala-Met-Ser)-Arg-Pro-R₄-R₅-His-Phe-Gly-R₆-
35 Asp-R₇-Glu-Asp-Arg-Tyr-Tyr-Arg-Glu-Asn-Met-R₈-Arg-
(Tyr-Pro-Asn-Gln)-Y

(II)

- 7 -

wherein R_4 and R_5 are the same as in formula I;

R_6 is either Asn or Ser;

R_7 is either Tyr or Trp;

5 R_8 is an amino acid residue selected from His, Tyr and Asn;

one or more residues within brackets maybe present or absent with the proviso that if they are present they are attached to the rest of the peptide in sequence; and X and Y may each independently be absent or

10 independently be one or more additional amino acid residues.

Preferably in a sequence according to formula II, R_5 is Ile, R_7 is Tyr and R_8 is His or Tyr. Below are preferred sequences of formula II relating to bovine, 15 ovine and human prion proteins respectively:

Seq. I.D. No: 7

20 X-(Ser-Ala-Met-Ser)-Arg-Pro-Leu-Ile-His-Phe-Gly-Ser-Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-Arg-Glu-Asn-Met-His-Arg-(Tyr-Pro-Asn-Gln)-Y;

Seq. I.D. No: 8

25 X-(Ser-Ala-Met-Ser)-Arg-Pro-Leu-Ile-His-Phe-Gly-Asn-Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-Arg-Glu-Asn-Met-Tyr-Arg-(Tyr-Pro-Asn-Gln)-Y; and

Seq. I.D. No: 9

30 X-(Ser-Ala-Met-Ser)-Arg-Pro-Ile-Ile-His-Phe-Gly-Ser-Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-Arg-Glu-Asn-Met-His-Arg-(Tyr-Pro-Asn-Gln)-Y.

Particularly preferred sequences are selected from Seq. I.D. No: 42

35 Ser-Ala-Met-Ser-Arg-Pro-Leu-Ile-His-Phe-Gly-Asn-Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-Gly-Cys; and

- 8 -

Seq. I.D. No: 43

Ser-Ala-Met-Ser-Arg-Pro-Leu-Ile-His-Phe-Gly-
Ser-Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-Gly-Cys.

5 Again it will be apparent that our invention encompasses significant sub-fragments of the sequence according to Formula II and a preferred general sub-fragment has the sequence:-

10 X-(Ser-Ala-Met-Ser)-Arg-Pro-R₄-R₅-His-Phe-Gly-R₆-
Asp-R₇-Glu-Asp-Arg-Tyr-Tyr-(Arg-Glu-Asn-Met)-Y

wherein R₄ to R₇, X and Y are as defined in formula II and one or more residues in brackets may be present or
15 absent. Preferably, R₅ is Ile and R₇ is Tyr. It will be appreciated that preferred sub-fragments relating to bovines, ovines and humans are respectively;

Seq. I.D. No: 10

20 X-(Ser-Ala-Met-Ser)-Arg-Pro-Leu-Ile-His-Phe-Gly-Ser-
Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-(Arg-Glu-Asn-Met)-Y;

Seq. I.D. No: 11

X-(Ser-Ala-Met-Ser)-Arg-Pro-Leu-Ile-His-Phe-Gly-Asn-
25 Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-(Arg-Glu-Asn-Met)-Y; and

Seq. I.D. No: 12

X-(Ser-Ala-Met-Ser)-Arg-Pro-Ile-Ile-His-Phe-Gly-Ser-
Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-(Arg-Glu-Asn-Met)-Y.

30

Our invention provides in respect of region C a synthetic peptide sequence according to general formula III:

35 X-(Asn-Met-R₈-Arg)-Tyr-Pro-Asn-Gln-Val-Tyr-Tyr-Arg-
Pro-R₉-Asp-R₁₀-Tyr-R₁₁-Asn-Gln-Asn-Asn-Phe-Val-His-
(Asp-Cys-Val-Asn)-Y

- 9 -

(III)

wherein R_8 is an amino acid residue selected from His, Tyr and Asn;

5 R_9 is Val or Met;

R_{10} is an amino acid residue selected from Gln, Glu and Arg;

10 R_{11} is Ser or Asn; one or more residues within brackets maybe present or absent with the proviso that if they are present they are attached to the rest of the peptide in sequence and X and Y may each independently be absent or independently be one or more additional amino acid residues.

15 Preferably in a sequence according to formula III, R_8 is His or Tyr and R_{11} is Ser. Below are preferred sequences of formula III relating to bovine, ovine and human prion proteins respectively:

Seq. I.D. No: 13

20 X-(Asn-Met-His-Arg)-Tyr-Pro-Asn-Gln-Val-Tyr-Tyr-Arg-Pro-Val-Asp-Gln-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-(Asp-Cys-Val-Asn)-Y;

Seq. I.D. No: 14

25 X-(Asn-Met-Tyr-Arg)-Tyr-Pro-Asn-Gln-Val-Tyr-Tyr-Arg-Pro-Val-Asp-Arg-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-(Asp-Cys-Val-Asn)-Y; and

Seq. I.D. No: 15

30 X-(Asn-Met-His-Arg)-Tyr-Pro-Asn-Gln-Val-Tyr-Tyr-Arg-Pro-Met-Asp-Glu-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-(Asp-Cys-Val-Asn)-Y.

35 Particularly preferred sequences are selected from Seq. I.D. No: 44
Asn-Met-Tyr-Arg-Tyr-Pro-Asn-Gln-Val-Tyr-Tyr-Arg-Pro-Val-Asp-Arg-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-Gly-Cys; and

- 10 -

Seq. I.D. No: 45

Asn-Met-His-Arg-Tyr-Pro-Asn-Gln-Val-Tyr-Tyr-Arg-Pro-Val-
 Asp-Gln-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-Gly-Cys.

- 5 Significant sub-fragments of the sequence according to formula III form part of this invention and a preferred sub-fragment has the sequence:

10 X-(Arg-Tyr-Pro-Asn)-Gln-Val-Tyr-Tyr-Arg-Pro-R₉-Asp-
 R₁₀-Tyr-R₁₁-Asn-Gln-Asn-Asn-Phe-Val-His-
 (Asp-Cys-Val-Asn)-Y.

- 15 Preferred sub-fragments relating to bovines, ovines and humans are respectively:

Seq. I.D. No: 16

 X-(Arg-Tyr-Pro-Asn)-Gln-Val-Tyr-Tyr-Arg-Pro-Val-Asp-
 Gln-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-
 20 (Asp-Cys-Val-Asn)-Y;

Seq. I.D. No: 17

 X-(Arg-Tyr-Pro-Asn)-Gln-Val-Tyr-Tyr-Arg-Pro-Val-Asp-
 Arg-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-
 25 (Asp-Cys-Val-Asn)-Y; and

Seq. I.D. No: 18

 X-(Arg-Tyr-Pro-Asn)-Gln-Val-Tyr-Tyr-Arg-Pro-Met-Asp-
 Glu-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-
 30 (Asp-Cys-Val-Asn)-Y.

In respect of region D, our invention provides a synthetic peptide sequence according to general formula IV:

35

 X-(Tyr-Tyr-R₁₂-R₁₃-Arg)-R₁₄-R₁₅-Ser-R₁₆-R₁₇-R₁₈-Leu-Phe-Ser-
 Ser-Pro-Pro-Val-Ile-Leu-Leu-Ile-Ser-Phe-Leu-Ile-Phe-

- 11 -

Leu-R₁₉-Val-Gly-Y

(IV)

wherein R₁₂ is Asp or Gln;R₁₃ is Gly or absent;5 R₁₄ is Gly or Arg;R₁₅ is Ala or Ser;R₁₆ is Ser or absent;R₁₇ is an amino acid residue selected from Ala, Thr, Met and Val;10 R₁₈ is Val or Ile;

R₁₉ is Ile or Met; one or more residues within brackets may be present or absent with the proviso that if they are present they are attached to the rest of the peptide in sequence and X and Y may each independently be absent or independently be one or more additional amino acid residues.

Preferably in a sequence according to formula IV R₁₂ is Gln, R₁₃ is absent, R₁₄ is Gly, R₁₆ is absent, R₁₇ is Val or Met and R₁₉ is Ile.

20 Preferred sequences of formula IV relating to bovine and ovine and to human prion proteins respectively are given below:

Seq. I.D. No: 19

25 X-(Tyr-Tyr-Gln-Arg)-Gly-Ala-Ser-Val-Ile-Leu-Phe-Ser-Ser-Pro-Pro-Val-Ile-Leu-Leu-Ile-Ser-Phe-Leu-Ile-Phe-Leu-Ile-Val-Gly-Y; and

Seq. I.D. No: 20

30 X-(Tyr-Tyr-Gln-Arg)-Gly-Ser-Ser-Met-Val-Leu-Phe-Ser-Ser-Pro-Pro-Val-Ile-Leu-Leu-Ile-Ser-Phe-Leu-Ile-Phe-Leu-Ile-Val-Gly-Y.

Clearly, it will be recognised that the present invention includes with its ambit significant sub-
35 fragments of the sequence according to formula IV and a preferred general sub-fragment has the sequence:

X-(-R₁₄-R₁₅-Ser-R₁₆-R₁₇)-R₁₈-Leu-Phe-Ser-Ser-Pro-Pro-Val-

- 12 -

Ile-(Leu-Leu-Ile-Ser)-Y

Wherein R_{14} to R_{18} , X and Y are as defined in formula IV and one or more residues within brackets may be present or absent as in formula IV.

It is preferred that in a sub-fragment as given above, R_{14} is Gly, R_{16} is absent and R_{17} is Val or Met. Below are preferred sub-fragments relating to bovines and ovines and to humans respectively:

Seq. I.D. No: 21

X-(Gly-Ala-Ser-Val)Ile-Leu-Phe-Ser-Ser-Pro-Pro-Val-Ile-(Leu-Leu-Ile-Ser)-Y; and

Seq. I.D. No: 22

X-(Gly-Ser-Ser-Met)-Val-Leu-Phe-Ser-Ser-Pro-Pro-Val-Ile-(Leu-Leu-Ile-Ser)-Y.

Our invention provides in respect of Region E three synthetic polypeptide sequences according to general formulae Va, Vb and Vc:

X-(Pro-Gly-Gly- R_{20})-Trp-Asn-Thr-Gly-Gly-Ser-Arg-Tyr-Pro-Gly-Gln-Gly-Ser-Pro-Gly-Gly-Asn-Arg-Tyr-Pro-Pro-Gln-Gly-(Gly- R_{21} - R_{22} -Trp)-Y (Va);

X-(Gly-Gly- R_{21} - R_{22} -Trp)-Gly-Gln-Pro-His-Gly-Gly-Gly- R_{23} -Trp(Gly-Gln-Pro-His)-Y (Vb); and

X-(Gly-Gly-Gly-Trp)-Gly-Gln-Gly-Gly- R_{24} - R_{25} -His- R_{26} -Gln-Trp-Asn-Lys-Pro- R_{27} -Lys-Pro-Lys-Thr- R_{28} - R_{29} -Lys(-His- R_{30} -Ala-Gly)-Y (Vc)

Wherein R_{20} , R_{21} , R_{23} and R_{24} are each independently either Gly or absent;

R_{22} either Gly or Thr;

R_{25} is either Thr or Ser;

- 13 -

R_{26} is an amino acid residue selected from Gly, Ser and Asn;

R_{27} and R_{28} are each independently either Asn or Ser;

R_{29} is an amino acid residue selected from Met, Leu and Phe;

R_{30} is either Val or Met; one or more residues within brackets maybe present or absent with the proviso that if they are present they are attached to the rest of the peptide in sequence; and X and Y may each independently be absent or independently be one or more additional amino acid residues.

With regard to formulae Va to Vc above, it is preferred that R_{22} is Gly, R_{23} is absent, R_{26} is Gly or Ser, R_{27} is Ser, R_{28} is Asn and R_{29} is Met.

Preferred bovine sequences of prion proteins according to formulae Va to Vc are given below:

Seq. I.D. No: 23

X-(Pro-Gly-Gly-Gly)-Trp-Asn-Thr-Gly-Gly-Ser-Arg-Tyr-
Pro-Gly-Gln-Gly-Ser-Pro-Gly-Gly-Asn-Arg-Tyr-Pro-Pro-
Gln-Gly-(Gly-Gly-Gly-Trp)-Y;

Seq. I.D. No: 24

X-(Gly-Gly-Gly-Trp)-Gly-Gln-Pro-His-Gly-Gly-Gly-Trp-
(Gly-Gln-Pro-His)-Y; and

Seq. I.D. No: 25

X-(Gly-Gly-Gly-Trp)-Gly-Gln-Gly-Gly-Thr-His-Gly-Gln-
Trp-Asn-Lys-Pro-Ser-Lys-Pro-Lys-Thr-Asn-Met-Lys
(-His-Val-Ala-Gly)-Y.

Preferred sequences of formulae Va to Vc relating to ovine prion proteins are as follows:

Seq. I.D. No: 26

X-(Pro-Gly-Gly-Gly)-Trp-Asn-Thr-Gly-Gly-Ser-Arg-Tyr-

- 14 -

Pro-Gly-Gln-Gly-Ser-Pro-Gly-Gly-Asn-Arg-Tyr-Pro-
Pro-Gln-Gly-(Gly-Gly-Gly-Trp)-Y;

Seq. I.D. No: 27

5 X-(Gly-Gly-Gly-Trp)-Gly-Gln-Pro-His-Gly-Gly-
Gly-Trp-(Gly-Gln-Pro-His)-Y; and

Seq. I.D. No: 28

10 X-(Gly-Gly-Gly-Trp)-Gly-Gln-Gly-Gly-Ser-His-
Ser-Gln-Trp-Asn-Lys-Pro-Ser-Lys-Pro-Lys-Thr-
Asn-Met-Lys(-His-Val-Ala-Gly)-Y.

Preferred sequences of formulae Va to Vc relating
to human prion proteins are as follows:

15

Seq. I.D. No: 29

X-Pro-Gly-Gly-Gly-Trp-Asn-Thr-Gly-Gly-Ser-Arg-Tyr-Pro-
Gly-Gln-Gly-Ser-Pro-Gly-Gly-Asn-Arg-Tyr-Pro-Pro-
Gln-Gly-(Gly-Gly-Gly-Trp)-Y;

20

Seq. I.D. No: 30

X-(Gly-Gly-Gly-Trp)-Gly-Gln-Pro-His-Gly-Gly-Gly-
Trp-(Gly-Gln-Pro-His)-Y; and

25 Seq. I.D. No: 31

X-(Gly-Gly-Gly-Trp)-Gly-Gln-Gly-Gly-Gly-Thr-His-Ser-
Gln-Trp-Asn-Lys-Pro-Ser-Lys-Pro-Lys-Thr-Asn-Met-Lys
(-His-Met-Ala-Gly)-Y.

30 Particularly preferred sequences of formulae Va to
Vc consist of:

Seq. I.D. No: 49

35 Gly-Gly-Trp-Asn-Thr-Gly-Gly-Ser-Arg-Tyr-Pro-Gly-Gln-
Gly-Ser-Pro-Gly-Gly-Asn-Arg-Tyr-Pro-
Pro-Gln-Gly-Gly-Gly-Cys;

Seq. I.D. No: 46

- 15 -

Gly-Gln-Pro-His-Gly-Gly-Gly-Trp-Gly-Gln-Pro-His-Gly-Gly-
Gly-Trp-Gly-Gln-Pro-His-Gly-Gly-Gly-Trp-Gly-Cys; and

Seq. I.D. No: 47

5

Gly-Gln-Gly-Gly-Ser-His-Ser-Gln-Trp-Asn-Lys-Pro-
Ser-Lys-Pro-Lys-Thr-Asn-Met-Lys-His-Val-Gly-Cys.

We have noted that in the nucleic acid sequence
corresponding to region E, it is possible for the
repeating sequence of formula Vb to have undergone a
frame shift of either +1 or -1. Such frame shifts give
rise to altered sequences in region E of the prion
protein and our invention provides a synthetic
polypeptide having a sequence wherein a repeat in region
E has undergone a -1 frame shift as given in formula VI:

X-(R₃₁-R₃₂-Trp-R₃₃)-Trp-Leu-Gly-R₃₄-R₃₅-R₃₆-Trp-R₃₇
(Trp-Leu-Gly-R₃₈)-Y
(VI)

Wherein R₃₁ and R₃₅ are each independently either Ala
or Thr; R₃₂ and R₃₆ are each independently an amino acid
residue selected from Ser, Pro and Thr;
R₃₃ and R₃₇ are each independently either Trp or Arg;
R₃₄ and R₃₈ are each independently an amino acid residue
selected from Ala, Ser, Pro and Thr; one or more
residues within brackets maybe present or absent with
the proviso that if they are present they are attached
to the rest of the peptide in sequence; and X and Y may
each independently be absent or independently be one or
more, additional amino acid residues.

With regard to -1 frame shifts in respect of region
E in bovines, it is preferred that R₃₁ is Ala, R₃₂, R₃₄,
R₃₆ and R₃₈ are each independently either Ser or Pro, R₃₃
and R₃₇ are Arg and R₃₅ is Ala.

It should be noted that preferred sequences for -1
frame shifts in region E of ovines differ in some
respects to those given for bovines and in a preferred


- 16 -

ovine sequence R_{31} , R_{32} , R_{33} , R_{35} , R_{36} and R_{37} correspond to the definitions given for formula VI above; and R_{34} and R_{38} are each independently selected from Ser, Pro and Thr.

5 In a preferred human sequence according to formula VI R_{31} , R_{34} , R_{35} and R_{38} are each Ala, R_{32} and R_{36} are each independently either Ser or Pro and R_{33} and R_{37} are both Trp.

10 As mentioned previously, the frame shift may be +1 in the repeat portion of region E and this gives rise to different amino acid sequences. Accordingly, our invention provides a synthetic polypeptide according to formula VII below which relates to a +1 frame shift in the repeat of region E:

15



20 Wherein R_{39} and R_{43} are each independently either Ser or Asn; R_{40} and R_{44} are each independently an amino acid residue selected from Pro, Leu and His, R_{41} and R_{45} are each independently Val or Glu; R_{42} and R_{46} are each independently selected from Val, Ala, Asp and Gly; one
25 or more residues within brackets maybe present or absent with the proviso that if they are present they are attached to the rest of the peptide in sequence; and X and Y may each independently be absent or
30 independently be one or more, additional amino acid residues.

A preferred bovine sequence according to formula VII comprises R_{39} and R_{43} each being Ser, R_{42} and R_{46} each being independently either Val or Ala and R_{44} being either Pro or Leu; with the other R groups being as
35 defined in formula VII.



A preferred sequence according to formula VII relating to ovines is the same as given in general

- 17 -

formula VII except R_{42} and R_{46} are each independently selected from Val, Ala and Asp.

With regard to a preferred human sequence according to formula VII, R_{39} and R_{43} are Ser, R_{40} and R_{44} are each independently Pro or Leu, R_{41} and R_{45} are Val and R_{42} and R_{46} are each independently either Asp or Gly.

Our invention also provides a synthetic peptide sequence relating to region F and having either the general formula VIIIa or VIIIb:



Wherein R_{47} is either Ile or Val;

20 R_{48} and R_{52} are each independently either Gln or Glu;

R_{49} is either Val or Thr;

R_{50} is either Val or Ile;

R_{51} is an amino acid residue selected from Ile, Thr and Val;

25 R_{52} is Gln or Glu;

R_{53} is either Arg or Lys;

R_{54} is either Asp or Gln;

R_{55} is Gly or is absent;

R_{56} is either Gly or Arg;

30 R_{57} is either Ala or Ser;

R_{58} is Ser or absent;

R_{59} is an amino acid residue selected from Ala, Thr, Met and Val;

35 one or more residues within brackets maybe present or absent with the proviso that if they are present they are attached to the rest of the peptide in sequence; and X and Y may each independently be absent or independently be one or more, e.g. 3, additional amino

- 18 -

acid residues.

It is preferred in formula VIIIa that R_{49} is Thr and in formula VIIIb that R_{51} is Ile, R_{53} is Arg, R_{54} is Gln, R_{55} is absent, R_{56} is Gly, R_{57} is Ala and R_{58} is absent.

5 Most preferred bovine, ovine and human sequences according to formulae VIIIa and VIIIb are given below in order:

Seq. I.D. No: 32

10 X-(Asn-Phe-Val-His)-Asp-Cys-Val-Asn-Ile-Thr-Val-Lys-
Glu-His-Thr-Val-Thr-Thr-Thr-Thr-Lys-Gly-Glu-Asn-
Phe-Thr-Glu-(Thr-Asp-Ile-Lys)-Y
bovine (VIIIa), and

15 Seq. I.D. No: 33

X-(Met-Cys-Ile-Thr)-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-
Tyr-Tyr-Gln-Arg-(Gly-Ala-Ser-Val)-Y
bovine (VIIIb);

20 Seq. I.D. No: 34

X-(Asn-Phe-Val-His)-Asp-Cys-Val-Asn-Ile-Thr-Val-Lys-
Gln-His-Thr-Val-Thr-Thr-Thr-Thr-Lys-Gly-Glu-Asn-
Phe-Thr-Glu-(Thr-Asp-Ile-Lys)-Y
ovine (VIIIa), and

25

Seq. I.D. No:35

X-(Met-Cys-Ile-Thr)-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-
Tyr-Tyr-Gln-Arg-(Gly-Ala-Ser-Val)-Y
ovine (VIIIb);

30

Seq. I.D. No:36

X-(Asn-Phe-Val-His)-Asp-Cys-Val-Asn-Ile-Thr-Ile-Lys-
Gln-His-Thr-Val-Thr-Thr-Thr-Thr-Lys-Gly-Glu-Asn-
Phe-Thr-Glu-(Thr-Asp-Val-Lys)-Y

35

human (VIIIa), and

Seq. I.D. No:37

- 19 -

X-(Met-Cys-Ile-Thr)-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-
Tyr-Tyr-Gln-Arg-(Gly-Ser-Ser-Met)-Y
human (VIIIb).

5 Particularly preferred sequences according to
formula VIIIa and VIIIb are selected from

Seq. I.D. No: 50

10 Val-Asn-Ile-Thr-Val-Lys-Gln-His-Thr-Val-Thr-Thr-Thr-
Lys-Gly-Glu-Asn-Phe-Thr-Glu-Gly-Cys; and

Seq. I.D. No: 48

15 Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-
Ser-Gln-Ala-Tyr-Tyr-Gln-Arg.

Synthetic polypeptides according to any one
formulae I to VIIIb above without X and Y being present
20 will of course be useful, for example, in the production
of antibodies. However, when X or Y are present they
may be any length but preferably less than 20 amino
acids, more preferably less than 10, eg. 3 to 6. It
will of course be appreciated that a sequence according
25 to any one of formulae I to VIIIb may constitute a
protein with X and Y being major portions of the protein
with the antigenic sequence being for example, part of
an exposed loop on a globular protein.


It is preferred that if X or Y are present they are
30 relatively short sequences, typically 1 to 3 residues
long. In most instances X is preferably absent and Y is
1 or 2 residues long, e.g. -Cys r -G r -Cys.

All the sequences herein are stated using the
standard I.U.P.A.C. three-letter-code abbreviations for
35 amino acid residues defined as follows: Gly-Glycine,
Ala-Alanine, Val-Valine, Leu-Leucine, Ile-Isoleucine,
Ser-Serine, Thr-Threonine, Asp-Aspartic acid, Glu-

- 20 -

Glutamic acid, Asn-Asparagine, Gln-Glutamine, Lys-Lysine, His-Histidine, Arg-Arginine, Phe-Phenylalanine, Tyr-Tyrosine, Trp-Tryptophan, Cys-Cysteine, Met-Methionine and Pro-Proline.

- 5 Polypeptides according to the invention may be used to raise antibodies which will cross-react with prion proteins produced in a wide range of organisms. Our analyses have shown that since the conformational, topographic and electrostatic properties of polypeptides
10 according to the invention are such that they are highly likely to elicit the production of antibodies which will cross-react with prion proteins from several or many organisms, further advantages may arise from combining several variant polypeptides in a larger polypeptide.
15 Such a polypeptide may have the general formula (IX):



- wherein F and G may each independently be a polypeptide
20 or sub-fragment according to any one of Formulae I to VIIIB, L is a linking sequence, a, b and c are each independently 0 or 1 and m and n are each positive numbers e.g. between 1 and 10 inclusive. L is preferably a short, conformationally flexible section of
25 polypeptide chain such as, for example and without limit (Seq. I.D. No: 38) Gly-Gly-Gly-Gly-Gly, (Seq. I.D. No: 39) Gly-Pro-Gly-Pro-Gly-Pro or (Seq. I.D. No: 40) Gly-Ser-Ala-Gly-Ser-Gly-Ala. It should be clear that each repeat may optionally have a different variant of a
30 polypeptide according to the invention.

- It should be noted certain of the C-terminals correspond to N-terminals, particularly formula Va to formula Vb, formula Vc to formula I, formula I to formula II, formula II to formula III, formula III to
35 formula VIIIA and formula VIIIB to formula IV. Advantage may be taken to this correspondence when producing larger polypeptides according to formula IX.

- 21 -

Linking sequences together with respective X and Y moieties may be omitted and residues in brackets may be selected so that either the regions of correspondence are duplicated or some or all of the duplicated residues are omitted. In the latter case it will be seen that the C-terminal of one polypeptide merges with the N-terminal of the other polypeptide.

Polyvalent determinant analogues as defined by Formula IX may be either what is referred to as pseudohomopolyvalent, wherein variants of essentially the same determinant analogue are repeated in a single polypeptide chain and/or heteropolyvalent, wherein distinct determinants are included in a single polypeptide. In addition, simple homopolyvalent polypeptide immunogens, which contain multiple copies of the same variant of one of the determinant analogues according to any one of formulae I to VIIIb, would also be expected to be effective, and are also included within the scope of the present invention.

It is to be understood that any antigenically significant subfragments and/or antigenically significant variants of the above-identified polypeptide sequences which retain the general form and function of the parent polypeptide are included within the scope of this invention. In particular, the substitution of any of the specific residues by residues having comparable conformational and/or physical properties, including substitution by rare (but naturally occurring, e.g. D-stereoisomers) or synthetic amino acid analogues, is included. For example, substitution of a residue by another in the same Set, as defined below, is included within the ambit of the invention; Set 1 - Ala, Val, Leu, Ile, Phe, Tyr, Trp and Met; Set 2 - Ser, Thr, Asn and Gln; Set 3 - Asp and Glu; Set 4 - Lys, His and Arg; Set 5 - Asn and Asp; Set 6 - Glu and Gln; Set 7 - Gly, Ala, Pro, Ser and Thr. D-stereoisomers of all amino acid types, may be substituted, for example, D-Phe, D-Tyr and

- 22 -


D-Trp.

In preferred embodiments of the invention, X and Y if present may independently include one or more segments of protein sequence with the ability to act as a T-cell epitope. For example, segments of amino acid sequence of the general formula 1-2-3-4, where 1 is Gly or a charged amino acid (e.g. Lys, His, Arg, Asp or Glu), 2 is a hydrophobic amino acid (e.g. Ile, Leu, Val, Met, Tyr, Phe, Trp, Ala), 3 is either a hydrophobic amino acid (as defined above) or an uncharged polar amino acid (e.g. Asn, Ser, Thr, Pro, Gln, Gly), and 4 is a polar amino acid (e.g. Lys, Arg, His, Glu, Asp, Asn, Gln, Ser, Thr, Pro), appear to act as T-cell epitopes in at least some instances (Rothbard, J.B. & Taylor, W.R. (1988). A sequence pattern in common to T-cell epitopes. The EMBO Journal 7(1): 93-100). Similarly segments can be of the sequence 1'-2'-3'-4'-5', wherein 1' is equivalent to 1 as defined earlier, 2' to 2, 3' and 4' to 3, and 5' to 4 (ibid). Both forms are included within the scope of the present invention and one or more T-cell epitopes (preferably less than five) which may be of the type defined above or may be of other structure and which may be separated by spacer segments of any length or composition, preferably less than five amino acid residues in length and comprising for example residues selected from Gly, Ala, Pro, Asn, Thr, Ser or polyfunctional linkers such as non- α amino acids. It is possible for a C- or N-terminal linker to represent a complete protein, thus obviating the possible need for conjugation to a carrier protein.

Also included within the scope of this invention are derivatives of the polypeptides according to any one formulae I to VIIIb in which X or Y are or include a "retro-inverso" amino acid, i.e. a bifunctional amine having a functional group corresponding to an amino acid. For example an analogue according to the invention and containing a retro-inverso amino acid may

- 23 -

have the formula:



where R is any functional group, e.g. a glycine side chain, and A1 and A2 are preferably each a copy of one of the analogues defined herein (but not necessarily the same) attached by its N- or C-terminal end. T-cell epitopes may optionally be included as discussed earlier.

Retro-inverso modification of peptides involves the reversal of one or more peptide bonds to create analogues more resistant than the original molecule to enzymatic degradation and offer one convenient route to the generation of branched immunogens which contain a high concentration of epitope for a medium to large immunogen. The use of these compounds in large-scale solution synthesis of retro-inverso analogues of short-chain biologically active peptides has great potential.

Peptides according to the invention may be synthesised by standard peptide synthesis techniques, for example using either standard 9-fluorenyl-methoxycarbonyl (F-Moc) chemistry (see, for example, Atherton, E. and Sheppard, R. C. (1985) J. Chem. Soc. Chem. Comm. 165) or standard butyloxycarbonate (T-Boc) chemistry although it is noted that, more recently, the fluorenylmethoxycarbonyl (Fmoc)/tert-butyl system, developed by Sheppard *et al* has found increasingly wide application (Sheppard, R.C. 1986 Science Tools, The LKB Journal 33, 9). The correctness of the structure and the level of purity, which will normally be in excess of 85%, should be carefully checked, and particular attention be given to the correctness of internal disulphide bridging arrangements when present. Various chromatographic analyses, including high performance liquid chromatography, and spectrographic analyses,

- 24 -

including Raman spectroscopy, may for example be employed for this purpose.

It is to be understood that the polypeptides according to the invention may be synthesised by any
5 conventional method, either directly using manual or automated peptide synthesis techniques as mentioned above, or indirectly by RNA or DNA synthesis and conventional techniques of molecular biology and genetic engineering. Such techniques may be used to produce
10 hybrid proteins containing one or more of the polypeptides inserted into another polypeptide sequence.

Another aspect of the present invention therefore provides a DNA molecule coding for at least one synthetic polypeptide according to the invention,
15 preferably incorporated into a suitable expression vector replicable in microorganisms or in mammalian cells. The DNA may also be part of the DNA sequence for a longer product e.g. the polypeptides may be expressed as parts of other proteins into which they
20 have been inserted by genetic engineering. One practical guide to such techniques is "Molecular cloning: a laboratory manual" by Sambrook, J., Fritsch, E.F. and Maniatis, T. (2nd Edition, 1989).

It should be noted that analogues incorporating
25 retro-inverso amino acid derivatives cannot be made directly using a recombinant DNA system. However, the basic analogues can, and they can then be purified and chemically linked to the retro-inverso amino-acids using standard peptide/organic chemistry. A practical and
30 convenient novel procedure for the solid-phase synthesis on polyamide-type resin of retro-inverso peptides has been described recently [Gazerro, H., Pinori, M. & Verdini, A.S. (1990). A new general procedure for the solid-phase synthesis of retro-inverso peptides. In
35 "Innovation and Perspectives in Solid Phase Synthesis" Ed. Roger Epton. SPCC (UK) Ltd, Birmingham, UK].

The polypeptides are optionally linked to a carrier

- 25 -

molecule, either through chemical groups within the polypeptides themselves or through additional amino acids added at either the C- or N-terminus, and which may be separated from the polypeptide themselves or surrounded by one or more additional amino acids, in order to render them optimal for their immunological function. Many linkages are suitable and include for example use of the side chains of Tyr, Cys and Lys residues. Suitable carriers include, for example, purified protein derivative of tuberculin (PPD), tetanus toxoid (TT), cholera toxin and its B subunit, ovalbumin, bovine serum albumin (BSA), soybean trypsin inhibitor (STI), miramyl dipeptide (MDP) and analogues thereof, diphtheria toxoid (DPT), keyhole limpet haemocyanin (KLH) and Braun's lipoprotein although other suitable carriers will be readily apparent to the skilled person. For example, multiple antigen peptides may be used such as those comprising a polylysyl core, e.g. heptalysyl, bearing reactive amine termini. Polypeptide antigens according to the invention may be reacted with, or synthesised on, the amino termini and different polypeptide antigens may be reacted with the same core or carrier. When using PPD as a carrier for polypeptides according to the invention, a higher titre of antibodies is achieved if the recipient of the polypeptide-PPD conjugate is already tuberculin sensitive, e.g. by virtue of earlier BCG vaccination. In the case of a human vaccine it is worth noting that in the UK and many other countries the population is routinely offered BCG vaccination and is therefore largely PPD-sensitive. Hence PPD is expected to be a preferred carrier for use in such countries.

The mode of coupling the polypeptide to the carrier will depend on the nature of the materials to be coupled. For example, a lysine residue in the carrier may be coupled to a C-terminal or other cysteine residue in a polypeptide by treatment with N-γ

- 26 -

-maleimidobutyryloxy-succinimide (Kitagawa, T. & Ackawa, T. (1976) J. Biochem. 79, 233). Alternatively, a lysine residue in the carrier may be conjugated to a glutamic or aspartic acid residue in the peptide using

5 isobutylchloroformate (Thorell, J.I. De Larson, S.M. (1978) Radioimmunoassay and related techniques: Methodology and clinical applications, p.288). Other coupling reactions and reagents have been described in the literature.

10 The polypeptides, either alone or linked to a carrier molecule, may be administered by any route (eg parenteral, nasal, oral, rectal, intra-vaginal), with or without the use of conventional adjuvants (such as aluminium hydroxide or Freund's complete or incomplete

15 adjuvants) and/or other immunopotentiating agents. The invention also includes formulation of polypeptides according to the invention in slow-release forms, such as a sub-dermal implant or depot comprising, for example, liposomes (Allison, A.C. & Gregoriadis, G.

20 (1974) Nature (London) 252, 252) or biodegradable microcapsules manufactured from co-polymers of lactic acid and glycolic acids (Gresser, J. D. and Sanderson, J. E. (1984) in "Biopolymer Controlled Release Systems" pp 127-138, Ed. D. L. Wise).

25 Polypeptides according to the invention may be used either alone or linked to an appropriate carrier, as:

(a) As ligands in assays of, for example, serum from patients or animals;

(b) Peptide vaccines, for use in prophylaxis;

30 (c) As quality control agents in testing, for example, binding levels of antibodies raised against the polypeptides;

(d) As antigenic agents for the generation of monoclonal or polyclonal antibodies by immunisation of

35 an appropriate animal, such antibodies being of use for (i) the scientific study of prion proteins, (ii) as diagnostic agents, e.g. as part of immunohistochemical

- 27 -

reagents, (iii) for the passive immunisation of animals or patients, either as a treatment for encephalopathies or in combination with other agents, (iv) as a means of targeting other agents to regions comprising prion proteins, such agents either being linked covalently or otherwise associated, e.g. as in liposomes containing such agents and incorporating antibodies raised against any of the antigenic polypeptides and (v) for use as immunogens to raise anti-idiotypic antibodies; such anti-idiotypic antibodies also form part of this invention. The invention further provides for genetically engineered forms or sub-components, especially V_H regions, of antibodies raised against the polypeptides, and of ovinised, bovinised, or humanised forms of antibodies initially raised against the polypeptides in other animals, using techniques described in the literature; and

(e) The treatment of encephalopathies, either by displacing the binding of prion proteins to human or animal cells or by disturbing the three-dimensional organisation of the protein in vivo; as well as aiding the scientific study of prion proteins in vitro.

In respect of detection and diagnosis, of prion proteins or antibodies against prion proteins, the skilled person will be aware of a variety of immunoassay techniques known in the art, inter alia, sandwich assay, competitive and non-competitive assays and the use of direct and indirect labelling.

A further aspect of the invention provides a kit for detecting prion proteins or antibodies against prion proteins which comprises at least one synthetic polypeptide according to the invention.

The preparation of polyclonal or monoclonal antibodies, humanised forms of such antibodies (see, for example, Thompson K. M. et al (1986) Immunology 58, 157-160), single domain antibodies (see, for example, Ward, E. S., Gussow, D., Griffiths, A. D., Jones, P. and

- 28 -

Winter, G. (1989) Nature 341, 544-546), and antibodies which might cross the blood-brain barrier, which bind specifically to a synthetic polypeptide according to the present invention, may be carried out by conventional
5 means and such antibodies are considered to form part of this invention. Antibodies according to the invention are, inter alia, of use in a method of diagnosing mammalian encephalopathies which comprises incubating a sample of tissue or body fluid of mammal with an amount
10 of antibody as described herein and determining whether, and if desired the extent to which and/or rate at which, cross-reaction between said sample and said antibody occurs. Diagnostic kits which contain at least one of said antibodies also form part of this invention.

15 A further aspect of the invention provides synthetic polypeptides for use in therapy or prophylaxis of mammalian encephalopathies and/or stimulating the mammalian immune system and/or blocking the cellular binding or aggregation of the prion proteins and for the
20 preparation of medicaments suitable for such uses. Also included are pharmaceutical compositions containing, as active ingredient, at least one polypeptide or polypeptide-carrier conjugate as described herein in association with one or more pharmaceutically acceptable
25 adjuvants, carriers and/or excipients. The compositions may be formulated for oral, rectal, nasal or especially parenteral administration (including intra-CNS administration).

The invention further provides a method of therapy
30 or prophylaxis of mammalian encephalopathies and/or of stimulating the mammalian immune system and/or of blocking the cellular binding or aggregation of the prion proteins, which comprises administering an amount of a polypeptide as hereinbefore defined, either in
35 isolation or in combination with other agents for the treatment of encephalopathies.

Discrimination between natural PrP^C and PrP^{Sc} is

- 29 -

highly desired since PrP^c is found in normal subjects and both PrP^c and PrP^{sc} are found in a diseased subject. We have found that peptide sequences according to the invention, preferably those relating to regions A, B and C, and significant sub-fragments thereof may be used to discriminate between natural PrP^c and infective PrP^{sc}. Also, antibodies raised against these peptide sequences and sub-fragments and the nucleotide sequences which code for such peptide sequences and sub-fragments may also be used to discriminate between PrP^c and PrP^{sc}. Accordingly, the invention provides a method of discriminating between PrP^c and PrP^{sc} in which a sample is contacted with a substance selected from peptide sequences according to the invention, preferably those relating to regions A, B and C, and significant sub-fragments thereof, antibodies raised against said sequences and sub-fragments and the presence or absence of PrP^{sc} is determined.

In some instances discrimination may be enhanced by pretreatment of the sample, for example by pre-digestion with enzymes e.g. proteinase K, or denaturation by strong alkali e.g. 6M guanidine hydrochloride or by a combination of such treatments.

It will be preferable to use the peptide sequences, antibodies and nucleotide sequences which relate to the specific subject under test, e.g. bovine sequences and antibodies for cattle, ovine sequences and antibodies for sheep.

It may be advantageous to immunise with a cocktail containing (i) a given analogue conjugated to more than one type of carrier molecule, and/or (ii) more than one kind of analogue conjugated to the same carrier molecule. Moreover, any of the peptide analogues, their conjugates, and cocktails thereof may be administered in any suitable adjuvant or delivery system, and more than one adjuvant or delivery system may be combined to form

- 30 -

a so-called "super-cocktail". Preferred adjuvants and delivery systems include aluminium hydroxide (alum), liposomes, micelles, niosomes, ISCOMS, Brauns lipoprotein and whole-cell or components of microbial animal vaccines.

Example 1

A preferred bovine form of formula II (Seq. I.D. No: 41) Ala-Met-Ser-Arg-Pro-Leu-Ile-His-Phe-Gly-Ser-Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-Arg-Glu-Asn-Met-His-Arg-Gly-Cys (related to Seq. I.D. No: 7) in which the C-terminal Y extension is Gly-Cys according to the invention is synthesised using standard solid-phase Fmoc methodologies. The peptide is cleaved from the resin in the presence of trifluoroacetic acid and subsequent purification is achieved by gel filtration, ion exchange chromatography and reverse phase high performance liquid chromatography. The peptide is conjugated to a variety of carriers by MBS (m-Maleimido-benzoyl-N-hydroxy succinimide ester), a well-known hetero-bifunctional reagent.

Examples of carriers include KLH, BSA and TT which have been shown to provide necessary immunopotentiating properties to B cell epitopes.

The peptide carrier conjugates are emulsified in Freund's Complete Adjuvant and are administered intramuscularly to mice. Subsequent booster injections are given in Freund's Incomplete Adjuvant.

The ensuing serum antibody response is monitored throughout the immunisation schedule by enzyme immunoassay (ELISA) using immobilised antigen (formula II), coupled to BSA, the serum sample under test, and an enzyme-labelled anti-mouse antibody.

In this example, use of carriers, adjuvants and delivery systems and booster injections are effected in order to determine an optimal protocol for producing anti-formula II antibodies.

Example 2

- 31 -

Antibodies to formula II are used as diagnostic reagents for assaying the presence of prion protein in serum, in "cell carriers" in serum and in tissue biopsies of injected animal species.

- 5 A direct enzyme immunoassay (ELISA) can detect the presence of extracted prion protein by its immobilisation onto a solid substrate. Reaction of mouse antisera raised to formula II with native prion protein is detected with an enzyme-labelled anti-mouse antiserum. The reaction is quantified by addition of a
10 suitable substrate and reading the optical density of the colour produced.

- 15 Furthermore, immunohistochemical diagnosis of prion proteins in tissue biopsies can be performed by reacting anti-formula II antibodies with paraffin wax embedded or frozen tissue. Reactions can be detected using a standard indirect immunoperoxidase technique.

- 32 -

Example 3MATERIALS AND METHODSPeptide Synthesis

5 The following peptides were synthesised using
standard solid-phase Fmoc methodologies.

Peptide II: (Seq. I.D. No: 42)

10 Ser-Ala-Met-Ser-Arg-Pro-Leu-Ile-His-Phe-Gly-
Asn-Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-Gly-Cys

(A preferred ovine sub-fragment of formula II).

15

Peptide BII: (Seq. I.D. No: 43)

Ser-Ala-Met-Ser-Arg-Pro-Leu-Ile-His-Phe-Gly-
Ser-Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-Gly-Cys

20

(A preferred bovine sub-fragment of formula II).

Peptide III: (Seq. I.D. No: 44)

25

Asn-Met-Tyr-Arg-Tyr-Pro-Asn-Gln-Val-Tyr-Tyr-Arg-Pro-Val-
Asp-Arg-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-Gly-Cys

30 (A preferred ovine sequence of formula III (p8, ln
30-32)).

Peptide BIII: (Seq. I.D. No: 45)

35 Asn-Met-His-Arg-Tyr-Pro-Asn-Gln-Val-Tyr-Tyr-Arg-Pro-Val-
Asp-Gln-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-Gly-Cys

(A preferred bovine sequence of formula III (p8, ln
26-28)).

- 33 -

Peptide Vb: (Seq. I.D. No: 46)

Gly-Gln-Pro-His-Gly-Gly-Gly-Trp-Gly-Gln-Pro-His-Gly-Gly-
Gly-Trp-Gly-Gln-Pro-His-Gly-Gly-Gly-Trp-Gly-Cys

5

(A preferred ovine/bovine sequence of formula Vb).

Peptide Vc: (Seq. I.D. No: 47)

10

Gly-Gln-Gly-Ser-His-Trp-Gln-Trp-Asn-Lys-Pro-
Ser-Lys-Pro-Lys-Thr-Asp-Lys-His-Val-Gly-Cys

(A preferred ovine sequence of formula Vc).

15

Peptide VIIIb: (Seq. I.D. No: 48)

Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-
Ser-Gln-Ala-Tyr-Tyr-Gln-Arg

20

(A preferred ovine/bovine sequence of formula VIIIb).

Peptide Va: (Seq. I.D. No: 49)

Gly-Gly-Trp-Asn-Thr-Gly-Gly-Ser-Arg-Tyr-
Pro-Gly-Gln-Gly-Ser-Pro-Gly-Gly-Asn-Arg-Tyr-Pro-
Pro-Gln-Gly-Gly-Gly-Cys

25

Peptide VIIIa: (Seq. I.D. No: 50)

Val-Asn-Ile-Thr-Val-Lys-Gln-His-Thr-Val-Thr-Thr-Thr-
Lys-Gly-Glu-Asn-Phe-Lys-Glu-Gly-Cys

30

(A preferred ovine sequence of formula VIIIa).

Peptide I: (Seq. I.D. No: 51)

Lys-His-Met-Ala-Gly-Ala-Ala-Ala-Ala-Gly-Ala-
Val-Val-Gly-Gly-Leu-Gly-Gly-Tyr-Met-Leu-Gly-Ser-Ala-
Met-Ser-Arg-Gly-Cys.

35

- 34 -

Peptides I, II, BII, III, BIII, Va, Vb, Vc and VIIIA were synthesised with the C-terminal extension according to the invention. The peptides were cleaved from the resin in the presence of trifluoroacetic acid and subsequent
5 purification was achieved by reverse phase high performance liquid chromatography. All peptides had a purity of 85% or more.

Conjugation of peptides to ovalbumin

10

Peptides were conjugated through their C-terminal (peptides II, BII, III, BIII, Vb and Vc) or N-terminal (peptide VIIIB) Cys residues. Peptides were dissolved in dimethyl sulphoxide (DMSO) to a concentration of 10 mg/ml.

15 Preactivated ovalbumin (Pierce, Imject Kit) was resuspended in 1 ml of distilled water, and equal volumes of preactivated ovalbumin and peptide were mixed and the solution allowed to stand at room temperature for 3 hours. The conjugate was dialysed overnight against phosphate
20 buffered saline (PBS) to remove the DMSO and unconjugated peptide.

The extent of conjugation was determined by measuring the free-thiol content using an Ellman's assay and by
25 monitoring the increase in the molecular mass of the conjugate by SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis).

Generation of rabbit antisera.

30

Antiserum was raised against each of the peptide conjugates in two female New Zealand White rabbits. Each rabbit received an amount of conjugate equivalent to 40 µg of peptide for both the primary inoculation and the boosters.
35 Rabbits were injected as follows:

Day 0: Conjugate in Freund's Complete Adjuvant (1:1, v/v) intramuscularly.

Day 21: Conjugate in Freund's Incomplete Adjuvant

- 35 -

(1:1, v/v) intramuscularly.

Day 31: Conjugate on its own intraperitoneally.

5 Animals were bled on day 41, and the sera assayed for anti-peptide antibody by ELISA (using free peptide as the coating antigen). The sera were also used in immunoblot and dot blot assays to see if they could recognise proteins from the brain homogenates.

10 Preparation of brain homogenates

Scrapie-free brain material was obtained from a flock of New Zealand sheep in quarantine.

15 Scrapie-infected brain material was obtained from a Department of Agriculture and had been histopathologically diagnosed as being scrapie infected.

20 BSE-infected brain material was obtained via a government Agriculture Department and had been histopathologically certified as being BSE infected.

BSE-free material was obtained through a private source.

25 Ha27-30 is brain material obtained from an inbred hamster scrapie model, which has been shown to contain a high level of the scrapie-infective agent. It was used as a positive control.

30 Small samples of infected and uninfected brain were weighed and 10% (w/v) homogenates made up in 10% (v/v) solution of Sarkosyl in 25 mM Tris-HCl pH 7.4 (homogenisation buffer). The homogenate was incubated at 4°C for 30 mins and then spun at 6000 x g for 30 mins. The supernatant was
35 collected and the protein content determined using the BCA protein assay kit (Pierce). The protein concentration was adjusted to 3 mg/ml using homogenisation buffer.

- 36 -

ELISA (Enzyme-linked immunosorbent assay)

A 8 μ M solution of free peptide in PBS was used as the coating antigen. Microtitre plates were coated by adding 50 μ l of the antigen concentration to each well and then incubating for 1 hour at 37°C to allow binding to occur. Each well was washed 5 times, for 2 minutes, with 300 μ l of PBS containing 0.05% Tween 20. After washing, the plates were blocked by incubating for 1 hour at 37°C with PBS containing 0.3% Tween 20 and 3% non-fat milk. An aliquot of 50 μ l of primary antibody (i.e. antisera) diluted in PBS was added to the appropriate wells and the plates incubated for 1 hour at 37°C. Plates were washed as before, and then incubated with Horseradish peroxidase conjugated swine anti-rabbit immunoglobulin (anti Ig/HRP) at a dilution of 1:1000 in PBS for 1 hour at 37°C. The plates were washed and 50 μ l of OPD (O-phenylenediamine dihydrochloride substrate (10 mg/ml) in citrate buffer) added to each well and the reaction allowed to proceed at room temperature for 10 minutes, before being stopped by the addition of sulphuric acid. The absorbance of each well was measured at 492 nm using an ELISA plate reader. The titres were recorded as the dilutions which gave a positive optical density (OD) reading at least 3 times that of the background. The background was taken as the OD readings from wells which had not been coated with antigen.

Dot blot detection of PrP in brain homogenates

The brain homogenates prepared as described earlier were diluted 10-fold in PBS, and 100 μ l of homogenates (containing 30 μ g total protein) were applied to nitrocellulose filters using BRL 96 well vacuum manifold. The filters were dried for 1 hour at room temperature. The filters were then either wet with TBST (10 mM Tris-HCl pH7.4, 150 mM NaCl, 0.05% Tween 20) and PrP detected as described in the immunoblots, or the protein sample further treated. This further treatment of the sample included digestion of the protein on the filter using 100 μ g/ml proteinase K in TBST for 90 minutes at room temperature.

- 37 -

The proteinase K was inactivated by the addition of PMSF (phenylmethylsulphonyl fluoride) to a concentration of 5 mM in TBST. After protein digestion, some samples were also denatured by incubating the filters in 6M guanidine HCl containing 5 mM PMSF for 10 minutes. The guanidine was removed by 3 washes with TBST prior to incubation with the primary antibody.

Immunoblots. (Western Blots)

SDS-PAGE was performed on the brain homogenates, prepared as described previously, using standard techniques. The samples within the gel were transferred onto nitrocellulose in a Biorad transblot using Towbin Buffer (25 mM Tris, 190 mM glycine and 0.1% SDS) at 70 mA overnight. The nitrocellulose filter was blocked with 5% non-fat milk for 30 minutes at room temperature. The primary antibody (i.e. antisera) diluted in TBST was applied for 3 hours at room temperature, the filter washed 3 times for 10 minutes in TBST and the filter incubated for 2 hours at room temperature with the alkaline phosphatase-conjugated swine anti-rabbit immunoglobulin diluted at a dilution of 1:2000. After washing, the protein bands were detected using the NBT/BCIP (nitro-blue tetrazolium; 5-bromo-4-chloro-3-indolyl phosphate) substrate (Boehringer Mannheim).

RESULTS

- 1) Antibody titres: Good antibody titres to the peptides were obtained in all cases, though the level varied enormously. The peptide which gave the highest titre, also gave the best results in the dot blots.
- 2) Dot Blot Data: Uninfected tissue would be expected to contain only normal prion protein (PrP^c). Infected tissue would be expected to contain both the normal and the diseased (PrP^{sc}) forms of PrP.

PrP^c has a molecular weight of approximately 33-35 kD.

PrP^{sc} has a molecular weight of approximately 27-30 kD and is missing an N-terminal segment that is present in the PrP^c form. Otherwise, the amino acid sequence of PrP^{sc} is exactly the same as that of PrP^c. Probably
5 the most significant characteristic of PrP^{sc} is resistance to enzyme degradation with proteinase K, a non-specific protein-digesting enzyme.

When a protein sample is treated with proteinase K any
10 PrP^c should be completely digested. Therefore, in a sample containing only PrP^c, no PrP of any form will remain after proteinase K treatment. However, in a sample containing PrP^c and PrP^{sc} (i.e. a diseased sample), PrP^{sc} will remain after treatment.

15 There are antibodies currently available which recognise PrP^{sc}, but they only recognise the denatured protein. Therefore after proteinase K treatment, samples in the dot blot test were treated with
20 guanidine HCl, a denaturing agent, so that such antibodies could be used to detect PrP^{sc}.

The data are given in Tables I-V.

25 Peptide II:

Good titres. Dot blots appear to indicate that some discrimination is occurring. Negative results were obtained from the Western blots.

30 Peptide III:

Reasonable titres. Possibly there is recognition of a non-specific (perhaps non-protein) component in the proteinase K and guanidine treated samples. Negative results were obtained from the Western blots.

35

Peptide Vb:

Good titres. Although it appears that there might be some discrimination occurring, the Vb peptide in fact occurs within the N-terminal region that is missing in PrP^{sc}. One

would therefore not expect to see any recognition in the infected material treated with proteinase K and guanidine. However, one possible explanation is that the PrP^c present in the infected material has not been completely digested by the proteinase K. Negative results were obtained from the Western blots.

Peptide Vc: Excellent titres. These results are exactly as expected. As mentioned previously, antibodies which recognise PrP^{sc} generally only recognise the protein in its denatured state. Infected and uninfected samples, as well as containing PrP^{sc} and/or PrP^c in their "native" states, will also contain both PrP forms in various stages of denaturation due to natural protein turnover within cells. For this reason, antibodies would be expected to detect all three untreated samples. However proteinase K treatment will digest PrP^c and any partially denatured PrP^{sc} leading to a loss of antibody recognition in all samples (assuming the antibody only recognises denatured PrP). The addition of guanidine should restore antibody recognition in material which had originally contained PrP^{sc}. Western blots showed up the expected protein bands at the correct molecular weights.

Peptide VIIIb: Reasonable titre. There may be recognition of a non-specific component. Negative results were obtained from the Western blots.

Peptides BII & BII: The titres are reasonable and there are strong positive results from untreated normal and infected bovine brain material.

In summary, good anti-peptide titres obtained in all cases, the Western blots only worked well in the case of peptide Vc, which also gave the highest titre and the dot blots show that there is some discrimination occurring between PrP^c and PrP^{sc} with peptide Vc. Data from peptide II also suggests that discrimination is occurring.

Table I: Results from ovine peptide sequences

Pept/ Antibody Titre				Ovine Brain Material	DOT BLOT			West Blot
carrier ratio	number				Untrt	Prot K	Prot K + Gua	
II	8:1	93	20,000	infected	++	+	+	
				normal	++	-	-	
				Ha27-30	+/-	+/-	+/-	
II	8:1	94	20,000	infected	++	+	+	
				normal	++	-	-	
				Ha27-30	+	+	+	
III	6:1	101	5,000	infected	++	+	+	
				normal	++	+	+	
				Ha27-30	++	++	++	
III	6:1	102	5,000	infected	+++	+	+	
				normal	+++	+/-	+/-	
				Ha27-30	++	++	++	
Vc	5:1	97	160,000	infected	+++	+/-	+++	+
				normal	+++	+/-	+/-	
				Ha27-30	+++	++	+++	
Vc	5:1	98	320,000	infected	+++	+/-	+++	+
				normal	+++	+/-	+/-	
				Ha27-30	+++	+/-	+++	

- 41 -

Table II: Results from ovine peptide sequences

Pept/ carrier ratio	Antibody number	Titre	Bovine Brain Material	DOT BLOT			West Blot
				Untprt	Prot K	Prot K + Gua	
II	8:1	93	20,000	infected	++	+	+
				normal	++	+	+
				Ha27-30	+/-	+/-	+/-
II	8:1	94	20,000	infected	++	+	+
				normal	++	+	+
				Ha 27-30	+	+	+
III	6:1	101	5,000	infected	++	+	+
				normal	++	+	+
				Ha27-30	++	++	++
III	6:1	102	5,000	infected	++	+	+
				normal	++	+	+
				Ha27-30	++	++	++
Vc	5:1	97	160,000	infected	+++	+	++
				normal	++	+	+
				Ha27-30	+++	++	+++
Vc	5:1	98	320,000	infected	+++	+	++
				normal	++	+/-	+/-
				Ha27-30	+++	+/-	+++

Table III: Results from ovine/bovine peptide sequences

Pept/ carrier ratio	Antibody number	Titre	Ovine Brain Material	DOT BLOT			West Blot
				Untrt	Prot K + Gua	Prot K + Gua	
Vb 6:1	95	50,000	infected	++	+	+	
			normal	++	-	-	
			Ha27-30	++	++	++	
Vb 6:1	96	10,000	infected	++	+	+	
			normal	++	-	-	
			Ha27-30	++	++	++	
VIIIb 12:1	103	3,000	infected	++	+	+	
			normal	++	+	+	
			Ha27-30	++	+/-	+/-	
VIIIb 12:1	104	3,000	infected	+	+	+	
			normal	+	+	+	
			Ha27-30	+	+	+	

Table IV: Results from ovine/bovine peptide sequences

Pept/ carrier ratio	Antibody number	Titre	Bovine Brain Material	DOT BLOT			West Blot
				Untrt	Prot K + Gua	Prot K + Gua	
Vb 6:1	95	50,000	infected	++	+	+	
			normal	++	+	+	
			Ha27-30	++	++	++	
Vb 6:1	96	10,000	infected	++	+	+	
			normal	++	+	+	
			Ha27-30	++	++	++	
VIIIb 12:1	103	3,000	infected	++	+	+	
			normal	++	+	+	
			Ha27-30	++	+/-	+/-	
VIIIb 12:1	104	3,000	infected	+	+	+	
			normal	++	+/-	+/-	
			Ha27-30	+	+	+	

Table V: Results from bovine peptide sequences

Pept/ Antibody Titre carrier number ratio				Bovine Brain Material	DOT BLOT			West Blot
					Untrt	Prot K	Prot K + Gua	
BII	9:1	105	100,000	infected	+++	+	+	
				normal	+++	+	+	
				Ha27-30	+	+	+	
BII	9:1	106	100,000	infected	+++	+	+	
				normal	+++	+	+	
				Ha27-30	+	+	+	
BIII	5:1	107	20,000	infected	+++	+/-	+/-	
				normal	+++	+/-	+/-	
				Ha27-30	+	+	+	
BIII	5:1	108	10,000	infected	+++	+/-	+/-	
				normal	+++	+/-	+/-	
				Ha27-30	+	+	+	

(1) Information for Seq. I.D. No: 1

(A) Length: 31 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 1

Met Lys His Val Ala Gly Ala Ala Ala Ala Gly Ala Val Val Gly Gly
1 5 10 15
Leu Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro Leu Ile
20 25 30

(2) Information for Seq. I.D. No: 2

(i) Characterisation of sequence:

(A) Length: 31 Amino acids

(B) Type: Amino acid

(D) Topology: Linear.

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 2

Met Lys His Met Ala Gly Ala Ala Ala Ala Gly Ala Val Val Gly Gly
1 5 10 15
Leu Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro Ile Ile
20 25 30

- 45 -

- (3) Information for Seq. I.D. No: 3
- (i) Characterisation of sequence:
 - (A) Length: 17 Amino acids
 - (B) Type: Amino acid
 - (D) Topology: Linear
 - (ii) Type of molecule: Peptide
 - (xi) Description of sequence: Seq. I.D. No: 3

His Val Ala Gly Ala Ala Ala Gly Ala Val Val Gly Gly Leu Gly
1 5 10 15
Gly

- (4) Information for Seq. I.D. No: 4
- (i) Characterisation of sequence:
 - (A) Length: 17 Amino acids
 - (B) Type: Amino acid
 - (D) Topology: Linear
 - (ii) Type of molecule: Peptide
 - (xi) Description of sequence: Seq. I.D. No: 4

Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro Leu
1 5 10 15
Ile

- (5) Information for Seq. I.D. No: 5
- (i) Characterisation of sequence:
 - (A) Length: 17 Amino acids
 - (B) Type: Amino acid
 - (D) Topology: Linear
 - (ii) Type of molecule: Peptide
 - (xi) Description of sequence: Seq. I.D. No: 5

His Met Ala Gly Ala Ala Ala Gly Ala Val Val Gly Gly Leu Gly
1 5 10 15
Gly

- (6) Information for Seq. I.D. No: 6
- (i) Characterisation of sequence:
 - (A) Length: 17 Amino acids
 - (B) Type: Amino acid
 - (D) Topology: Linear
 - (ii) Type of molecule: Peptide
 - (xi) Description of sequence: Seq. I.D. No: 6

Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro Ile
 1 5 10 15
 Ile

- (7) Information for Seq. I.D. No: 7
- (i) Characterisation of sequence:
 - (A) Length: 29 Amino acids
 - (B) Type: Amino acid
 - (D) Topology: Linear
 - (ii) Type of molecule: Peptide
 - (xi) Description of sequence: Seq. I.D. No: 7

Ser Ala Met Ser Arg Pro Leu Ile His Phe Gly Ser Asp Tyr Glu Asp
 1 5 10 15
 Arg Tyr Tyr Arg Glu Asn Met His Arg Tyr Pro Asn Gln
 20 25

- (8) Information for Seq. I.D. No: 8
- (i) Characterisation of sequence:
 - (A) Length: 29 Amino acids
 - (B) Type: Amino acid
 - (D) Topology: Linear
 - (ii) Type of molecule: Peptide
 - (xi) Description of sequence: Seq. I.D. No: 8

Ser Ala Met Ser Arg Pro Leu Ile His Phe Gly Asn Asp Tyr Glu Asp
 1 5 10 15
 Arg Tyr Tyr Arg Glu Asn Met Tyr Arg Tyr Pro Asn Gln
 20 25

(12) Information for Seq. I.D. No: 12

(i) Characterisation of sequence:

(A) Length: 23 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 12

Ser Ala Met Ser Arg Pro Ile Ile His Phe Gly Ser Asp Tyr Glu Asp
1 5 10 15
Arg Tyr Tyr Arg Glu Asn Met
20

(13) Information for Seq. I.D. No: 13

(i) Characterisation of sequence:

(A) Length: 29 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 13

Asn Met His Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Val Asp Gln
1 5 10 15
Tyr Ser Asn Gln Asn Asn Phe Val His Asp Cys Val Asn
20 25

(14) Information for Seq. I.D. No: 14

(i) Characterisation of sequence:

(A) Length: 29 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 14

Asn Met Tyr Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Val Asp Arg
1 5 10 15
Tyr Ser Asn Gln Asn Asn Phe Val His Asp Cys Val Asn
20 25

- (15) Information for Seq. I.D. No: 15
- (i) Characterisation of sequence:
 - (A) Length: 29 Amino acids
 - (B) Type: Amino acid
 - (D) Topology: Linear
 - (ii) Type of molecule: Peptide
 - (xi) Description of sequence: Seq. I.D. No: 15

Asn	Met	His	Arg	Tyr	Pro	Asn	Gln	Val	Tyr	Tyr	Arg	Pro	Met	Asp	Glu
1					5					10				15	
Tyr	Ser	Asn	Gln	Asn	Asn	Phe	Val	His	Asp	Cys	Val	Asn			
			20					25							

- (16) Information for Seq. I.D. No: 16
- (i) Characterisation of sequence:
 - (A) Length: 26 Amino acids
 - (B) Type: Amino acid
 - (D) Topology: Linear
 - (ii) Type of molecule: Peptide
 - (xi) Description of sequence: Seq. I.D. No: 16

Arg	Tyr	Pro	Asn	Gln	Val	Tyr	Tyr	Arg	Pro	Val	Asp	Gln	Tyr	Ser	Asn
1					5				10					15	
Gln	Asn	Asn	Phe	Val	His	Asp	Cys	Val	Asn						
			20					25							

- (17) Information for Seq. I.D. No: 17
- (i) Characterisation of sequence:
 - (A) Length: 26 Amino acids
 - (B) Type: Amino acid
 - (D) Topology: Linear
 - (ii) Type of molecule: Peptide
 - (xi) Description of sequence: Seq. I.D. No: 17

Arg	Tyr	Pro	Asn	Gln	Val	Tyr	Tyr	Arg	Pro	Val	Asp	Arg	Tyr	Ser	Asn
1					5				10					15	
Gln	Asn	Asn	Phe	Val	His	Asp	Cys	Val	Asn						
			20					25							

- (18) Information for Seq. I.D. No: 18
- (i) Characterisation of sequence:
 - (A) Length: 26 Amino acids
 - (B) Type: Amino acid
 - (D) Topology: Linear
 - (ii) Type of molecule: Peptide
 - (xi) Description of sequence: Seq. I.D. No: 18

Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Met Asp Glu Tyr Ser Asn
1 5 10 15
Gln Asn Asn Phe Val His Asp Cys Val Asn
 20 25

- (19) Information for Seq. I.D. No: 19
- (i) Characterisation of sequence:
 - (A) Length: 29 Amino acids
 - (B) Type: Amino acid
 - (D) Topology: Linear
 - (ii) Type of molecule: Peptide
 - (xi) Description of sequence: Seq. I.D. No: 19

Tyr Tyr Gln Arg Gly Ala Ser Val Ile Leu Phe Ser Ser Pro Pro Val
1 5 10 15
Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly
 20 25

- (20) Information for Seq. I.D. No: 20
- (i) Characterisation of sequence:
 - (A) Length: 29 Amino acids
 - (B) Type: Amino acid
 - (D) Topology: Linear
 - (ii) Type of molecule: Peptide
 - (xi) Description of sequence: Seq. I.D. No: 20

Tyr Tyr Gln Arg Gly Ser Ser Met Val Leu Phe Ser Ser Pro Pro Val
1 5 10 15
Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly
 20 25

- 51 -

(21) Information for Seq. I.D. No: 21

(i) Characterisation of sequence:

(A) Length: 17 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 21

Gly Ala Ser Val Ile Leu Phe Ser Ser Pro Pro Val Ile Leu Leu Ile
 1 5 10 15
 Ser

(22) Information for Seq. I.D. No: 22

(i) Characterisation of sequence:

(A) Length: 17 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 22

Gly Ser Ser Met Val Leu Phe Ser Ser Pro Pro Val Ile Leu Leu Ile
 1 5 10 15
 Ser

(23) Information for Seq. I.D. No: 23

(i) Characterisation of sequence:

(A) Length: 31 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 23

Pro Gly Gly Gly Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly
 1 5 10 15
 Ser Pro Gly Gly Asn Arg Tyr Pro Pro n Gly Gly Gly Gly Trp
 20 25 30

(24) Information for Seq. I.D. No: 24

(i) Characterisation of sequence:

(A) Length: 16 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 24

Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His
 1 5 10 15

(25) Information for Seq. I.D. No: 25

(i) Characterisation of sequence:

(A) Length: 28 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 25

Gly Gly Gly Trp Gly Gln Gly Gly Thr His Gly Gln Trp Asn Lys Pro
 1 5 10 15
 Ser Lys Pro Lys Thr Asn Met Lys His Val Ala Gly
 20 25

(26) Information for Seq. I.D. No: 26

(i) Characterisation of sequence:

(A) Length: 31 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 26

Pro Gly Gly Gly Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly
 1 5 10 15
 Ser Pro Gly Gly Asn Arg Tyr Pro Pro Gln Gly Gly Gly Trp
 20 25 30

- (i) Characterisation of sequence:

(A) Length: 16 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

- (ii) Type of molecule: Peptide

- (xi) Description of sequence: Seq. I.D. No: 27

Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His
1 5 10 15

- (28) Information for Seq. I.D. No: 28

- (i) Characterisation of sequence:

(A) Length: 28 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

- (ii) Type of molecule: Peptide

- (xi) Description of sequence: Seq. I.D. No: 28

Gly Gly Gly Trp Gly Gln Gly Gly Ser His Ser Gln Trp Asn Lys Pro
1 5 10 15

Ser Lys Pro Lys Thr Asn Met Lys His Val Ala Gly
20 25

- (29) Information for Seq. I.D. No: 29

- (i) Characterisation of sequence:

(A) Length: 31 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

- (ii) - Type of molecule: Peptide

- (xi) Description of sequence: Seq. I.D. No: 29

Pro Gly Gly Gly Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly
1 5 10 15

Ser Pro Gly Gly Asn Arg Tyr Pro Pro Gln Gly Gly Gly Gly Trp
20 25 30

(30) Information for Seq. I.D. No: 30

(i) Characterisation of sequence:

(A) Length: 16 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 30

Gly	Gly	Gly	Trp	Gly	Gln	Pro	His	Gly	Gly	Gly	Trp	Gly	Gln	Pro	His
1				5					10					15	

(31) Information for Seq. I.D. No: 31

(i) Characterisation of sequence:

(A) Length: 29 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 31

Gly	Gly	Gly	Trp	Gly	Gln	Gly	Gly	Gly	Thr	His	Ser	Gln	Trp	Asn	Lys
1				5					10					15	
Pro	Ser	Lys	Pro	Lys	Thr	Asn	Met	Lys	His	Met	Ala	Gly			
				20					25						

(32) Information for Seq. I.D. No: 32

(i) Characterisation of sequence:

(A) Length: 31 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii)- Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 32

Asn	Phe	Val	His	Asp	Cys	Val	Asn	Ile	Thr	Val	Lys	Glu	His	Thr	Val
1				5					10					15	
Thr	Thr	Thr	Thr	Lys	Gly	Glu	Asn	Phe	Thr	Glu	Thr	Asp	Ile	Lys	
				20				25					30		

- Met Cys Ile Thr Gln Tyr Gln Arg Glu Ser Gln Ala Tyr Tyr Gln Arg
1 5 10 15
Gly Ala Ser Val
20

- ```

Asn Phe Val His Asp Cys Val Asn Ile Thr Val Lys Gln His Thr Val
1 5 10 15
Thr Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr Asp Ile Lys
 20 25 30

```

- Met Cys Ile Thr Gln Tyr Gln Arg Glu Ser Gln Ala Tyr Tyr Gln Arg  
1 5 10 15  
Gly Ala Ser Val  
20

(36) Information for Seq. I.D. No: 36

(i) Characterisation of sequence:

(A) Length: 31 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 36

Asn Phe Val His Asp Cys Val Asn Ile Thr Ile Lys Gln His Thr Val  
1                      5                      10                      15  
Thr Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr Asp Val Lys  
                    20                      25                      30

(37) Information for Seq. I.D. No: 37

(i) Characterisation of sequence:

(A) Length: 20 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 37

Met Cys Ile Thr Gln Tyr Glu Arg Glu Ser Gln Ala Tyr Tyr Gln Arg  
1                      5                      10                      15  
Gly Ser Ser Met  
                    20

(38) Information for Seq. I.D. No: 38

(i) Characterisation of sequence:

(A) Length: 5 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 38

Gly Gly Gly Gly Gly  
1                      5

- (39) Information for Seq. I.D. No: 39
- (i) Characterisation of sequence:
    - (A) Length: 6 Amino acids
    - (B) Type: Amino acid
    - (D) Topology: Linear
  - (ii) Type of molecule: Peptide
  - (xi) Description of sequence: Seq. I.D. No: 39

Gly Pro Gly Pro Gly Pro  
 1 5

- (40) Information for Seq. I.D. No: 40
- (i) Characterisation of sequence:
    - (A) Length: 7 Amino acids
    - (B) Type: Amino acid
    - (D) Topology: Linear
  - (ii) Type of molecule: Peptide
  - (xi) Description of sequence: Seq. I.D. No: 40

Gly Ser Ala Gly Ser Gly Ala  
 1 5

- (41) Information for Seq. I.D. No: 41
- (i) Characterisation of sequence:
    - (A) Length: 26 Amino acids
    - (B) Type: Amino acid
    - (D) Topology: Linear
  - (ii) Type of molecule: Peptide
  - (xi) Description of sequence: Seq. I.D. No: 41

Ala Met Ser Arg Pro Leu Ile His Phe Gly Ser Asp Tyr Glu Asp Arg  
 1 5 10 15  
 Tyr Tyr Arg Glu Asn Met His Arg Gly Cys  
 20 25

## (42) Information for Seq. I.D. No: 42

## (i) Characterisation of sequence:

(A) Length: 21 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

## (ii) Type of molecule: Peptide

## (xi) Description of sequence: Seq. I.D. No: 42

Ser Ala Met Ser Arg Pro Leu Ile His Phe Gly Asn Asp Tyr Glu Asp

1

5

10

15

Arg Tyr Tyr Gly Cys

20

## (43) Information for Seq. I.D. No: 43

## (i) Characterisation of sequence:

(A) Length: 21 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

## (ii) Type of molecule: Peptide

## (xi) Description of sequence: Seq. I.D. No: 43

Ser Ala Met Ser Arg Pro Leu Ile His Phe Gly Ser Asp Tyr Glu Asp

1

5

10

15

Arg Tyr Tyr Gly Cys

20

## (44) Information for Seq. I.D. No: 44

## (i) Characterisation of sequence:

(A) Length: 27 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

## (ii) Type of molecule: Peptide

## (xi) Description of sequence: Seq. I.D. No: 44

Asn Met Tyr Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Val Asp Arg

1

5

10

15

Tyr Ser Asn Gln Asn Asn Phe Val His Gly Cys

20

25

- (ii) Type of molecule: Peptide

- (xi) Description of sequence: Seq. I.D. No: 45

(46) Information for Seq. I.D. No: 46

- (ii) Type of molecule: Peptide

- (xi) Description of sequence: Seq. I.D. No: 46

(47) Information for Seq. I.D. No: 47

- (ii) Type of molecule: Peptide

- (xi) Description of sequence: Seq. I.D. No: 47

Gly Gln Gly Gly Ser His Ser Gln Trp Asn Lys Pro Ser Lys Pro Lys  
1 5 10 15  
Thr Asn Met Lys His Val Gly Cys  
20

## (48) Information for Seq. I.D. No: 48

## (i) Characterisation of sequence:

(A) Length: 15 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 48

Cys Ile Thr Gln Tyr Gln Arg Glu Ser Gln Ala Tyr Tyr Gln Arg  
 1 5 10 15

## (49) Information for Seq. I.D. No: 49

## (i) Characterisation of sequence:

(A) Length: 28 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 49

Gly Gly Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro  
 1 5 10 15

Gly Gly Asn Arg Tyr Pro Pro Gln Gly Gly Gly Cys  
 20 25

Peptide VIIIIa: (Seq. I.D. No: 50)

## (50) Information for Seq. I.D. No: 50

## (i) Characterisation of sequence:

(A) Length: 23 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 50

Val Asn Ile Thr Val Lys Gln His Thr Val Thr Thr Thr Thr Lys Gly  
 1 5 10 15

Glu Asn Phe Thr Glu Gly Cys  
 20

(51) Information for Seq. I.D. No: 51

(i) Characterisation of sequence:

(A) Length: 29 Amino acids

(B) Type: Amino acid

(D) Topology: Linear

(ii) Type of molecule: Peptide

(xi) Description of sequence: Seq. I.D. No: 51

Lys His Met Ala Gly Ala Ala Ala Gly Ala Val Val Gly Gly Leu  
1                      5                      10                      15  
Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Gly Cys.  
20                                      25

- 62 -

Claims


1. A synthetic polypeptide having at least one antigenic site of a prion protein.

5

2. A synthetic polypeptide as claimed in claim 1 in which the prion protein is of a form which only exists in nervous tissue of a mammal suffering from spongiform encephalopathy.

10

3. A synthetic polypeptide as claimed in claim 1 comprising sequence according to general formula (I):



wherein R<sub>1</sub> is an amino acid residue selected from Met,  
20 Leu and Phe;


R<sub>2</sub> is either Met or Val;

R<sub>3</sub> is Ala or is absent;

R<sub>4</sub> and R<sub>5</sub> are independently an amino acid residue  
selected from Leu, Ile and Met; one or more residues  
25 within brackets maybe present or absent with the proviso  
that if they are present they are attached to the rest  
of the peptide in sequence; and X and Y may each  
independently be absent or independently be one or more  
additional amino acid residues.

30

4. A synthetic polypeptide as claimed in claim 3  
comprising a sequence selected from Seq. I.D. No: 1





- 63 -

Seq. I.D. No:2

X-(Met-Lys-His-Met)-Ala-Gly-Ala-Ala-Ala-Ala-Gly-Ala-  
Val-Val-Gly-Gly-Leu-Gly-Gly-Tyr-Met-Leu-Gly-Ser-Ala-  
Met-Ser-(Arg-Pro-Ile-Ile)-Y.

5

5. A synthetic polypeptide as claimed in claim 3  
consisting of the sequence Seq. I.D. No: 51

Lys-His-Met-Ala-Gly-Ala-Ala-Ala-Ala-Gly-Ala-  
10 Val-Val-Gly-Gly-Leu-Gly-Gly-Tyr-Met-Leu-Gly-Ser-Ala-  
Met-Ser-Arg-Gly-Cys.

6. A significant sub-fragment of a sequence claimed in  
claim 3 preferably selected from

15

i) X-(His-R<sub>2</sub>-Ala-Gly)-Ala-Ala-Ala-R<sub>3</sub>-Gly-Ala-Val-  
Val-(Gly-Gly-Leu-Gly)-Y and;

ii) X-(Gly-Gly-Leu-Gly)-Gly-Tyr-Met-Leu-Gly-Ser-  
20 Ala-Met-Ser-(Arg-Pro-R<sub>4</sub>-R<sub>5</sub>)-Y

wherein R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, X and Y are as defined for formula  
I and one or more residues in brackets may be absent or  
present as in formula I.

25

7. A sub-fragment as claimed in claim 6 selected from

Seq. I.D. No: 3

i) X-(His-Val-Ala-Gly)-Ala-Ala-Ala-Ala-Gly-Ala-  
30 Val-Val-Gly-(Gly-Leu-Gly-Gly)-Y;

Seq. I.D. No: 4

ii) (Gly-Gly-Leu-Gly)-Gly-Tyr-Met-Leu-Gly-Ser-  
Ala-Met-Ser-(Arg-Pro-Leu-Ile)-Y

35

Seq. I.D. No: 5

i) X-(His-Met-Ala-Gly)-Ala-Ala-Ala-Ala-Gly-Ala-

- 64 -

Val-Val-Gly-(Gly-Leu-Gly-Gly)-Y; and

Seq. I.D. No: 6

5           ii) X-(Gly-Gly-Leu-Gly)-Gly-Tyr-Met-Leu-Gly-Ser-  
Ala-Met-Ser-(Arg-Pro-Ile-Ile)-Y.

8.   A synthetic polypeptide as claimed in claim 1  
comprising a sequence according to general formula II:

10

X-(Ser-Ala-Met-Ser)-Arg-Pro-R<sub>4</sub>-R<sub>5</sub>-His-Phe-Gly-R<sub>6</sub>-  
Asp-R<sub>7</sub>-Glu-Asp-Arg-Tyr-Tyr-Arg-Glu-Asn-Met-R<sub>8</sub>-Arg-  
(Tyr-Pro-Asn-Gln)-Y  
(II)

15

wherein R<sub>4</sub> and R<sub>5</sub> are the same as in formula I;

R<sub>6</sub> is either Asn or Ser;

R<sub>7</sub> is either Tyr or Trp;

R<sub>8</sub> is an amino acid residue selected from His, Tyr and  
20   Asn;

one or more residues within brackets maybe present or  
absent with the proviso that if they are present they  
are attached to the rest of the peptide in sequence; and  
X and Y may each independently be absent or  
25   independently be one or more additional amino acid  
residues.

9.   A synthetic polypeptide as claimed in claim 8  
comprising a sequence selected from

30

Seq. I.D. No: 7

X-(Ser-Ala-Met-Ser)-Arg-Pro-Leu-Ile-His-Phe-Gly-Ser-  
Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-Arg-Glu-Asn-Met-His-Arg-  
(Tyr-Pro-Asn-Gln)-Y;

35

Seq. I.D. No: 8

X-(Ser-Ala-Met-Ser)-Arg-Pro-Leu-Ile-His-Phe-Gly-Asn-  
Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-Arg-Glu-Asn-Met-Tyr-Arg-

- 65 -

(Tyr-Pro-Asn-Gln)-Y; and

Seq. I.D. No: 9

X-(Ser-Ala-Met-Ser)-Arg-Pro-Ile-Ile-His-Phe-Gly-Ser-  
 5 Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-Arg-Glu-Asn-Met-His-Arg-  
 (Tyr-Pro-Asn-Gln)-Y.

10. A synthetic polypeptide as claimed in claim 8  
 selected from Seq. I.D. No: 42

10 Ser-Ala-Met-Ser-Arg-Pro-Leu-Ile-His-Phe-Gly-  
 Asn-Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-Gly-Cys; and

Seq. I.D. No: 43

15 Ser-Ala-Met-Ser-Arg-Pro-Leu-Ile-His-Phe-Gly-  
 Ser-Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-Gly-Cys.

11. A significant sub-fragment of a sequence as claimed  
 in claim 8 preferably comprising the sequence:-

20 X-(Ser-Ala-Met-Ser)-Arg-Pro-R<sub>4</sub>-R<sub>5</sub>-His-Phe-Gly-R<sub>6</sub>-  
 Asp-R<sub>7</sub>-Glu-Asp-Arg-Tyr-Tyr-(Arg-Glu-Asn-Met)-Y

wherein R<sub>4</sub> to R<sub>7</sub>, X and Y are as defined in formula II  
 and one or more residues in brackets may be present or  
 25 absent.

12. A sub-fragment as claimed in claim 11 selected from

Seq. I.D. No: 10

30 X-(Ser-Ala-Met-Ser)-Arg-Pro-Leu-Ile-His-Phe-Gly-Ser-  
 Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-(Arg-Glu-Asn-Met)-Y;

Seq. I.D. No: 11

35 X-(Ser-Ala-Met-Ser)-Arg-Pro-Leu-Ile-His-Phe-Gly-Asn-  
 Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-(Arg-Glu-Asn-Met)-Y; and

Seq. I.D. No: 12

- 66 -

X-(Ser-Ala-Met-Ser)-Arg-Pro-Ile-Ile-His-Phe-Gly-Ser-  
Asp-Tyr-Glu-Asp-Arg-Tyr-Tyr-(Arg-Glu-Asn-Met)-Y.

13. A synthetic polypeptide as claimed in claim 1  
5 comprising a sequence according to general formula III:

X-(Asn-Met-R<sub>8</sub>-Arg)-Tyr-Pro-Asn-Gln-Val-Tyr-Tyr-Arg-  
Pro-R<sub>9</sub>-Asp-R<sub>10</sub>-Tyr-R<sub>11</sub>-Asn-Gln-Asn-Asn-Phe-Val-His-  
(Asp-Cys-Val-Asn)-Y

10 (III)

wherein R<sub>8</sub> is an amino acid residue selected from His,  
Tyr and Asn;

R<sub>9</sub> is Val or Met;

- 15 R<sub>10</sub> is an amino acid residue selected from Gln, Glu and  
Arg;

R<sub>11</sub> is Ser or Asn; one or more residues within brackets  
maybe present or absent with the proviso that if they  
are present they are attached to the rest of the peptide  
20 in sequence and X and Y may each independently be absent  
or independently be one or more additional amino acid  
residues.

14. A synthetic polypeptide as claimed in claim 13  
25 comprising a sequence selected from

Seq. I.D. No: 13

X-(Asn-Met-His-Arg)-Tyr-Pro-Asn-Gln-Val-Tyr-Tyr-Arg-  
Pro-Val-Asp-Gln-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-  
30 (Asp-Cys-Val-Asn)-Y;

Seq. I.D. No: 14

X-(Asn-Met-Tyr-Arg)-Tyr-Pro-Asn-Gln-Val-Tyr-Tyr-Arg-  
Pro-Val-Asp-Arg-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-  
35 (Asp-Cys-Val-Asn)-Y; and

- 67 -

Seq. I.D. No: 5

X-(Asn-Met--s-Arg)-Tyr-Pro-Asn-Gln-Val-Tyr-Tyr-Arg-  
 Pro-Met-Asp-Glu-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-  
 (Asp-Cys-Val-Asn)-Y.

5

15. A synthetic polypeptide as claimed in claim 14  
 selected from Seq. I.D. No: 44

Asn-Met-Tyr-Arg-Tyr-Pro-Asn-Gln-Val-Tyr-Tyr-Arg-Pro-Val-  
 Asp-Arg-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-Gly-Cys; and

10

Seq. I.D. No: 45

Asn-Met-His-Arg-Tyr-Pro-Asn-Gln-Val-Tyr-Tyr-Arg-Pro-Val-  
 Asp-Gln-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-Gly-Cys.

15 16. A significant sub-fragment of a sequence as claimed  
 in claim 13 preferably comprising the sequence:

X-(Arg-Tyr-Pro-Asn)-Gln-Val-Tyr-Tyr-Arg-Pro-R<sub>9</sub>-Asp-  
 R<sub>10</sub>-Tyr-R<sub>11</sub>-Asn-Gln-Asn-Asn-Phe-Val-His-  
 (Asp-Cys-Val-Asn)-Y.

20

wherein R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, X and Y are as defined in formula  
 (III).

25 17. A sub-fragment as claimed in claim 16 selected from

Seq. I.D. No: 16

X-(Arg-Tyr-Pro-Asn)-Gln-Val-Tyr-Tyr-Arg-Pro-Val-Asp-  
 Gln-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-  
 (Asp-Cys-Val-Asn)-Y;

30

Seq. I.D. No: 17

X-(Arg-Tyr-Pro-Asn)-Gln-Val-Tyr-Tyr-Arg-Pro-Val-Asp-  
 Arg-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-  
 (Asp-Cys-Val-Asn)-Y; and

35

- 68 -

Seq. I.D. No: 18

X-(Arg)-Tyr-Pro-Asn)-Gln-Val-Tyr-Tyr-Arg-Pro-Met-Asp-  
 Glu-Tyr-Ser-Asn-Gln-Asn-Asn-Phe-Val-His-  
 (Asp-Cys-Val-Asn)-Y.

5

18. A synthetic polypeptide as claimed in claim 1  
 comprising a sequence according to general formula IV:

X-(Tyr-Tyr-R<sub>12</sub>-R<sub>13</sub>-Arg)-R<sub>14</sub>-R<sub>15</sub>-Ser-R<sub>16</sub>-R<sub>17</sub>-R<sub>18</sub>-Leu-Phe-Ser-  
 10 Ser-Pro-Pro-Val-Ile-Leu-Leu-Ile-Ser-Phe-Leu-Ile-Phe-  
 Leu-R<sub>19</sub>-Val-Gly-Y  
 (IV)

wherein R<sub>12</sub> is Asp or Gln;

R<sub>13</sub> is Gly or absent;

15 R<sub>14</sub> is Gly or Arg;

R<sub>15</sub> is Ala or Ser;

R<sub>16</sub> is Ser or absent;

R<sub>17</sub> is an amino acid residue selected from Ala, Thr,  
 Met and Val;

20 R<sub>18</sub> is Val or Ile;

R<sub>19</sub> is Ile or Met; one or more residues within  
 brackets may be present or absent with the proviso that  
 if they are present they are attached to the rest of the  
 peptide in sequence and X and Y may each independently  
 25 be absent or independently be one or more additional  
 amino acid residues.

19. A synthetic polypeptide as claimed in claim 18  
 comprising a sequence selected from

30

Seq. I.D. No: 19


X-(Tyr-Tyr-Gln-Arg)-Gly-Ala-Ser-Val-Ile-Leu-Phe-Ser-  
 Ser-Pro-Pro-Val-Ile-Leu-Leu-Ile-Ser-Phe-Leu-Ile-Phe-  
 Leu-Ile-Val-Gly-Y; and

35 Seq. I.D. No: 20

X-(Tyr-Tyr-Gln-Arg)-Gly-Ser-Ser-Met-Val-Leu-Phe-Ser-Ser-  
 Pro-Pro-Val-Ile-Leu-Leu-Ile-Ser-Phe-Leu-Ile-  
 Phe-Leu-Ile-Val-Gly-Y.

- 69 -


20. A significant sub-fragment of a sequence as claimed in claim 18 preferably comprising the sequence:




Wherein R<sub>14</sub> to R<sub>18</sub>, X and Y are as defined in formula IV and one or more residues within brackets may be present or absent as in formula IV.

21. A sub-fragment as claimed in claim 20 selected from




Seq. I.D. No: 21



Seq. I.D. No: 22



22. A synthetic polypeptide as claimed in claim 1 comprising a sequence according to general formulae Va, Vb and Vc:



Wherein R<sub>20</sub>, R<sub>21</sub>, R<sub>23</sub> and R<sub>24</sub> are each independently

- 70 -

either Gly or absent;

R<sub>22</sub> either Gly or Thr;

R<sub>25</sub> is either Thr or Ser;

5 R<sub>26</sub> is an amino acid residue selected from Gly, Ser  
and Asn;

R<sub>27</sub> and R<sub>28</sub> are each independently either Asn or Ser;

R<sub>29</sub> is an amino acid residue selected from Met, Leu  
and Phe;

10 R<sub>30</sub> is either Val or Met; one or more residues  
within brackets maybe present or absent with the proviso  
that if they are present they are attached to the rest  
of the peptide in sequence; and X and Y may each  
independently be absent or independently be one or more  
additional amino acid residues.

15

23. A synthetic polypeptide as claimed in claim 22  
comprising a sequence selected from

Seq. I.D. No: 23

20 X-(Pro-Gly-Gly-Gly)-Trp-Asn-Thr-Gly-Gly-Ser-Arg-Tyr-  
Pro-Gly-Gln-Gly-Ser-Pro-Gly-Gly-Asn-Arg-Tyr-Pro-Pro-  
Gln-Gly-(Gly-Gly-Gly-Trp)-Y;

Seq. I.D. No: 24

25 X-(Gly-Gly-Gly-Trp)-Gly-Gln-Pro-His-Gly-Gly-Gly-Trp-  
(Gly-Gln-Pro-His)-Y;

Seq. I.D. No: 25

30 X-(Gly-Gly-Gly-Trp)-Gly-Gln-Gly-Gly-Thr-His-Gly-Gln-  
Trp-Asn-Lys-Pro-Ser-Lys-Pro-Lys-Thr-Asn-Met-Lys  
(-His-Val-Ala-Gly)-Y;

Seq. I.D. No: 26

35 X-(Pro-Gly-Gly-Gly)-Trp-Asn-Thr-Gly-Gly-Ser-Arg-Tyr-  
Pro-Gly-Gln-Gly-Ser-Pro-Gly-Gly-Asn-Arg-Tyr-Pro-  
Pro-Gln-Gly-(Gly-Gly-Gly-Trp)-Y;

Seq. I.D. No: 27

X-(Gly-Gly-Gly-Trp)-Gly-Gln-Pro-His-Gly-Gly-



- 71 -

Gly-Trp-(Gly-Gln-Pro-His)-Y;

Seq. I.D. No: 28

5 X-(Gly-Gly-Gly-Trp)-Gly-Gln-Gly-Gly-Ser-His-  
Ser-Gln-Trp-Asn-Lys-Pro-Ser-Lys-Pro-Lys-Thr-  
Asn-Met-Lys(-His-Val-Ala-Gly)-Y.

Seq. I.D. No: 29

10 X-Pro-Gly-Gly-Gly-Trp-Asn-Thr-Gly-Gly-Ser-Arg-Tyr-Pro-  
Gly-Gln-Gly-Ser-Pro-Gly-Gly-Asn-Arg-Tyr-Pro-Pro-  
Gln-Gly-(Gly-Gly-Gly-Trp)-Y;

Seq. I.D. No: 30

15 X-(Gly-Gly-Gly-Trp)-Gly-Gln-Pro-His-Gly-Gly-Gly-  
Trp-(Gly-Gln-Pro-His)-Y; and

Seq. I.D. No: 31

20 X-(Gly-Gly-Gly-Trp)-Gly-Gln-Gly-Gly-Gly-Thr-His-Ser-  
Gln-Trp-Asn-Lys-Pro-Ser-Lys-Pro-Lys-Thr-Asn-Met-Lys  
(-His-Met-Ala-Gly)-Y.

24. A synthetic polypeptide as claimed in claim 21  
selected from Seq. I.D. No: 49

25 Gly-Gly-Trp-Asn-Thr-Gly-Gly-Ser-Arg-Tyr-  
Pro-Gly-Gln-Gly-Ser-Pro-Gly-Gly-Asn-Arg-Tyr-Pro-  
Pro-Gln-Gly-Gly-Gly-Cys

Seq. I.D. No: 46

30 Gly-Gln-Pro-His-Gly-Gly-Gly-Trp-Gly-Gln-Pro-His-Gly-Gly-  
Gly-Trp-Gly-Gln-Pro-His-Gly-Gly-Gly-Trp-Gly-Cys; and


Seq. I.D. No: 47

35 Gly-Gln-Gly-Gly-Ser-His-Ser-Gln-Trp-Asn-Lys-Pro-  
Ser-Lys-Pro-Lys-Thr-Asn-Met-Lys-His-Val-Gly-Cys.

25. A synthetic polypeptide as claimed in claim 1

- 72 -

comprising a sequence according to formula VI:




5

Wherein  $R_{31}$  and  $R_{35}$  are each independently either Ala or Thr;  $R_{32}$  and  $R_{36}$  are each independently an amino acid residue selected from Ser, Pro and Thr;

10  $R_{33}$  and  $R_{37}$  are each independently either Trp or Arg;  
 $R_{34}$  and  $R_{38}$  are each independently an amino acid residue selected from Ala, Ser, Pro and Thr; one or more residues within brackets maybe present or absent with the proviso that if they are present they are attached to the rest of the peptide in sequence; and X and Y may  
 15 each independently be absent or independently be one or more, additional amino acid residues.

26. A synthetic polypeptide as claimed in claim 1  
 20 comprising a sequence according to formula VII:



25

Wherein  $R_{39}$  and  $R_{43}$  are each independently either Ser or Asn;  $R_{40}$  and  $R_{44}$  are each independently an amino acid residue selected from Pro, Leu and His,  $R_{41}$  and  $R_{45}$  are each independently Val or Glu;  $R_{42}$  and  $R_{46}$  are each  
 30 independently selected from Val, Ala, Asp and Gly; one or more residues within brackets maybe present or absent with the proviso that if they are present they are attached to the rest of the peptide in sequence; and X and Y may each independently be absent or  
 35 independently be one or more, additional amino acid residues.

27. A synthetic polypeptide as claimed in claim 1 comprising a sequence according to formula VIIIA or

- 73 -

VIIIb:

X-(Asn-Phe-Val-His)-Asp-Cys-Val-Asn-Ile-Thr-R<sub>47</sub>-Lys-  
 R<sub>48</sub>-His-Thr-Val-R<sub>49</sub>-Thr-Thr-Thr-Lys-Gly-Glu-Asn-  
 5 Phe-Thr-Glu-(Thr-Asp-R<sub>50</sub>-Lys)-Y  
 (VIIIa)

X-(Met-Cys-R<sub>51</sub>-Thr)-Gln-Tyr-R<sub>52</sub>-R<sub>53</sub>-Glu-Ser-Gln-Ala-  
 Tyr-Tyr-R<sub>54</sub>-R<sub>55</sub>-Arg-(R<sub>56</sub>-R<sub>57</sub>-Ser-R<sub>58</sub>-R<sub>59</sub>)-Y  
 10 (VIIIb)

Wherein R<sub>47</sub> is either Ile or Val;

R<sub>48</sub> and R<sub>52</sub> are each independently either Gln or Glu;

R<sub>49</sub> is either Val or Thr;

R<sub>50</sub> is either Val or Ile;

15 R<sub>51</sub> is an amino acid residue selected from Ile, Thr  
 and Val;

R<sub>52</sub> is Gln or Glu;

R<sub>53</sub> is either Arg or Lys;

R<sub>54</sub> is either Asp or Gln;

20 R<sub>55</sub> is Gly or is absent;

R<sub>56</sub> is either Gly or Arg;

R<sub>57</sub> is either Ala or Ser;

R<sub>58</sub> is Ser or absent;

25 R<sub>59</sub> is an amino acid residue selected from Ala, Thr,  
 Met and Val;

one or more residues within brackets maybe present or  
 absent with the proviso that if they are present they  
 are attached to the rest of the peptide in sequence; and  
 30 X and Y may each independently be absent or  
 independently be one or more, additional amino acid  
 residues.

28. A synthetic polypeptide as claimed in claim 27  
 35 comprising a sequence selected from:

Seq I.D. No: 32

X-(Asn-Phe-Val-His)-Asp-Cys-Val-Asn-Ile-Thr-Val-Lys-  
 Glu-His-Thr-Val-Thr-Thr-Thr-Thr-Lys-Gly-Glu-Asn-

- 74 -

Phe-Thr-Glu-(Thr-Asp-Ile-Lys)-Y;

Seq. I.D. No: 33

5 X-(Met-Cys-Ile-Thr)-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-  
Tyr-Tyr-Gln-Arg-(Gly-Ala-Ser-Val)-Y;

Seq. I.D. No: 34

10 X-(Asn-Phe-Val-His)-Asp-Cys-Val-Asn-Ile-Thr-Val-Lys-  
Gln-His-Thr-Val-Thr-Thr-Thr-Thr-Lys-Gly-Glu-Asn-  
Phe-Thr-Glu-(Thr-Asp-Ile-Lys)-Y;

Seq. I.D. No: 35

15 X-(Met-Cys-Ile-Thr)-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-  
Tyr-Tyr-Gln-Arg-(Gly-Ala-Ser-Val)-Y;

Seq. I.D. No: 36

20 X-(Asn-Phe-Val-His)-Asp-Cys-Val-Asn-Ile-Thr-Ile-Lys-  
Gln-His-Thr-Val-Thr-Thr-Thr-Thr-Lys-Gly-Glu-Asn-  
Phe-Thr-Glu-(Thr-Asp-Val-Lys)-Y; and

Seq. I.D. No: 37

25 X-(Met-Cys-Ile-Thr)-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-  
Tyr-Tyr-Gln-Arg-(Gly-Ser-Ser-Met)-Y.

29. A synthetic polypeptide as claimed in claim 27  
selected from Seq. I.D. No: 50

30


Val-Asn-Ile-Thr-Val-Lys-Gln-His-Thr-Val-Thr-Thr-Thr-Thr-  
Lys-Gly-Glu-Asn-Phe-Thr-Glu-Gly-Cys; and

Seq. I.D. No: 48

35 Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-Gln-Arg.

30. A synthetic polypeptide of general formula (IX):

- 75 -



wherein F and G may each independently be a polypeptide or sub-fragment according to any one of Formulae I to VIIIB, L is a linking sequence, a, b and c are each independently 0 or 1 and m and n are each positive numbers.

31. A synthetic polypeptide which comprises an antigenically significant subfragment and/or antigenically significant variant of the above-identified polypeptide sequences as claimed in 1 to 29.
32. A synthetic polypeptide as claimed in any one of the preceding claims additionally comprising a T-cell epitope.
33. A synthetic polypeptide as claimed in any one of the preceding claims including a retro-inverso amino acid.
34. A synthetic polypeptide as claimed in any one of preceding claims linked to a carrier.
35. A DNA molecule coding for at least one synthetic polypeptide as claimed in any one of claims 1 to 32.
36. A vaccine comprising at least one polypeptide as claimed in any one of claims 2 to 33 effective to promote prophylaxis against encephalopathies.
37. A kit for detecting prion proteins or antibodies against prion proteins which comprises at least one synthetic polypeptide as claimed in any one of claims 1 to 33.

- 76 -

38. A pharmaceutical composition containing as active ingredient, at least one polypeptide or polypeptide-carrier conjugate as claimed in any one of claims 2 to 34 in association with one or more pharmaceutically acceptable adjuvants, carriers and/or excipients.

39. Use of a synthetic polypeptide as claimed in any one of claims 2 to 34 for the preparation of a medicament for the therapeutic or prophylactic treatment of mammalian encephalopathies and/or blocking the cellular binding or aggregation of the prion proteins.

40. A method of therapy or prophylaxis of mammalian encephalopathies and/or of stimulating the mammalian immune system and/or of blocking the cellular binding or aggregation of the prion proteins, which comprises administering an amount of a polypeptide as claimed in any one of claims 2 to 34, either in isolation or in combination with other agents for the treatment of encephalopathies.

41. A method of detecting prion protein or antibodies against prion protein or antigen binding fragments thereof, which comprises incubating a sample with at least one polypeptide as claimed in any one of claims 1 to 34.

42. A method of discriminating between PrP<sup>C</sup> and PrP<sup>Sc</sup> in which a sample is contacted with a substance selected from peptide sequences as claimed in any one of claims 2 to 24 preferably those relating to regions A, B and C, and significant sub-fragments thereof, antibodies raised against said sequences and sub-fragments and the presence or absence of PrP<sup>Sc</sup> is determined.

43. An antibody or antigen binding fragment thereof

- 77 -

which specifically binds to a synthetic polypeptide as claimed in any one of claims 1 to 33.

44. A kit for detecting prion proteins or antibodies against prion proteins which contains an antibody or antigen binding fragment thereof, as claimed in claim 43.
45. A pharmaceutical composition comprising, as active ingredient, an antibody or antigen binding fragment as claimed in claim 43 in association with one or more pharmaceutically acceptable, carriers and/or excipients.
46. A method of therapy or prophylaxis of mammalian encephalopathies which comprises administering an antibody or antigen binding fragment as claimed in claim 43.
47. A method detecting prion proteins or antibodies against prion proteins which comprises incubating a sample with an antibody or antigen binding fragment as claimed in claim 43.
48. An anti-idiotypic antibody raised against an antibody or antigen binding fragment as claimed in claim 43.
49. A process for the manufacture of a synthetic polypeptide having at least one antigenic site of a prion protein, the process comprising the steps of coupling the residues using chemical, biological or recombinant techniques in per se and isolating the polypeptide as defined in any one of claims 1 to 33.
50. A process for the manufacture of an antibody which specifically binds to a synthetic polypeptide having at least one antigenic site of a prion protein, the process

- 78 -

comprising immunising a non-human mammal with said polypeptide and isolating the antibody as defined in claim 43.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 92/02246

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| <b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                     |
| According to International Patent Classification (IPC) or to both National Classification and IPC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                     |
| Int.Cl. 5 C07K7/06;<br>A61K37/02;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | C07K7/08;<br>A61K39/00;                                                                                                                                                                                                                                                                                                                                                   | C07K7/10;<br>G01N33/68<br><br>C07K15/00                                                                             |
| <b>II. FIELDS SEARCHED</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                     |
| Minimum Documentation Searched <sup>7</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                     |
| Classification System                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Classification Symbols                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                     |
| Int.Cl. 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | C07K                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                     |
| Documentation Searched other than Minimum Documentation<br>to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                     |
| <b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                     |
| Category <sup>9</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>                                                                                                                                                                                                                                                            | Relevant to Claim No. <sup>13</sup>                                                                                 |
| X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | <p>CELL<br/>vol. 46, 1 August 1986, CAMBRIDGE, NA US<br/>pages 417 - 428<br/>BASLER ET AL. 'Scrapie and Cellular PrP<br/>Isoforms Are Encoded by the Same<br/>Chromosomal Gene'</p> <p>see page 425, left column, paragraph 3<br/>see page 425, right column, paragraph 1;<br/>figure 3</p> <p style="text-align: center;">---</p> <p style="text-align: right;">-/--</p> | <p>1-4, 6-8,<br/>11, 13,<br/>16, 18,<br/>20,<br/>22-23,<br/>27-28,<br/>30, 31<br/>35,<br/>42-44,<br/>47, 49, 50</p> |
| <p><sup>9</sup> Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> |                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                     |
| <b>IV. CERTIFICATION</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                     |
| Date of the Actual Completion of the International Search                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Date of Mailing of this International Search Report                                                                                                                                                                                                                                                                                                                       |                                                                                                                     |
| 25 MARCH 1993                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 14. 04. 93                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                     |
| International Searching Authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Signature of Authorized Officer                                                                                                                                                                                                                                                                                                                                           |                                                                                                                     |
| EUROPEAN PATENT OFFICE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | FUHR C.K.B.                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                     |

| III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET) |                                                                                                                                                                                                                                                                                                                                                                                                    |                                                               |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| Category *                                                                 | Citation of Document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                                                                                                 | Relevant to Claim No.                                         |
| X                                                                          | <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA<br/>vol. 87, no. 7, April 1990, WASHINGTON US<br/>pages 2476 - 2480<br/>W. GOLDMANN ET AL. 'Two alleles of a neural protein gene linked to scrapie in sheep'<br/>see figure 2</p> <p>---</p>                                                                                                                                             | <p>1-4,6-9,<br/>11-14,<br/>16-23,<br/>27-28,<br/>30,35,49</p> |
| X                                                                          | <p>JOURNAL OF IMMUNOLOGY<br/>vol. 147, no. 10, 15 November 1991,<br/>BALTIMORE US<br/>pages 3568 - 3574<br/>M. ROGERS ET AL. 'EPITOPE MAPPING OF THE SYRIAN HAMSTER PRION PROTEIN UTILIZING CHIMERIC AND MUTANT GENES IN A VACCINIA VIRUS EXPRESSION SYSTEM'<br/>see discussion on page 3572-3573<br/>see page 3569, right column, paragraph 2;<br/>figure 6</p> <p>---</p>                        | <p>1-2,18,<br/>22-23,<br/>27,31,<br/>42-43,<br/>47,49-50</p>  |
| X                                                                          | <p>JOURNAL OF MOLECULAR RECOGNITION<br/>vol. 4, no. 2/3, June 1991,<br/>pages 85 - 91<br/>A.D. MARTINO 'Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-carrier Linked Synthetic Peptide Immunogens'<br/>see 'Antibody production , purification ....' on pages 87-89<br/>see page 86, left column<br/>see discussion on pages 89-90</p> <p>---</p> | <p>1-2,31,<br/>41-44,<br/>47,49-50</p>                        |
| X                                                                          | <p>JOURNAL OF VIROLOGY<br/>vol. 65, no. 7, July 1991,<br/>pages 3667 - 3675<br/>D.C. BOLTON ET AL. 'Molecular Location of a Species-Specific Epitope on the Hamster Scrapie Agent Protein'<br/>see discussion on page 3672-3674<br/>see page 3668, left column, paragraph 3 - right column, paragraph 4; table 2</p> <p>---</p>                                                                    | <p>1-3,31,<br/>42-44,<br/>47,49-50</p>                        |
| X                                                                          | <p>NEUROLOGY<br/>vol. 40, no. 3, March 1990,<br/>pages 513 - 517<br/>J. SAFAR ET AL. 'Scrapie-associated precursor proteins'<br/>see discussion on pages 516-517<br/>see page 514, left column, paragraph 4 - right column, paragraph 3</p> <p>-----</p>                                                                                                                                           | <p>1-2,31,<br/>42-44,<br/>47,49-50</p>                        |

# INTERNATIONAL SEARCH REPORT

I national application No.

PCT/GB92/02246

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 40 and 46 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compounds.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.